TGFβ2 and TGFβ3 mediate appropriate context-dependent phenotype of rat valvular interstitial cells

HIGHLIGHTS
- TGFβ signaling blockade causes valvulopathy; VICs may be the cellular target
- VICs express TGFβ receptors, ligands, and pSMAD2/3, indicating autocrine regulation
- TGFβ2 and TGFβ3 maintain VIC phenotype; TGFβRs altered shape, migration, and ECM
- Maintaining TGFβ3 transcription may reduce the potency of toxicity
TGFβ2 and TGFβ3 mediate appropriate context-dependent phenotype of rat valvular interstitial cells

Faye Wang,1 Cindy Zhang,1 Jae Kwagh,1 Brian Strassle,1 Jinqing Li,1 Minxue Huang,1 Yunling Song,1 Brenda Lehman,1 Richard Westhouse,1 Kamalavenkatesh Palanisamy,3 Vinay K. Holenarsipur,3 Robert Borzilleri,2 and Karen Augustine-Rauch1,4,*

SUMMARY

This study focused on characterizing the potential mechanism of valvular toxicity caused by TGFβ receptor inhibitors (TGFβRIs) using rat valvular interstitial cells (VICs) to evaluate early biological responses to TGFβR inhibition. Three TGFβRIs that achieved similar exposures in the rat were assessed. Two dual TGFβRI/RII inhibitors caused valvulopathy, whereas a selective TGFβRI inhibitor did not, leading to a hypothesis that TGFβ receptor selectivity may influence the potency of valvular toxicity. The dual valvular toxic inhibitors had the most profound effect on altering VIC phenotype including altered morphology, migration, and extracellular matrix production. Reduction of TGFβ expression demonstrated that combined TGFβ2/β3 inhibition by small interfering RNA or neutralizing antibodies caused similar alterations as TGFβRIs. Inhibition of TGFβ3 transcription was only associated with the dual TGFβRIs, suggesting that TGFβRII inhibition impacts TGFβ3 transcriptional regulation, and that the potency of valvular toxicity may relate to alteration of TGFβ2/β3-mediated processes involved in maintaining proper balance of VIC phenotypes in the heart valve.

INTRODUCTION

The TGFβ superfamily consists of at least 40 structurally and functionally related cytokines that are involved in various biological processes including embryonic development, extracellular matrix (ECM) formation, immune regulation, inflammation, and cancer invasion and metastasis (Massague and Chen, 2000). TGFβ is produced by leukocytes and other cell types, and its receptor-mediated signaling involves both autocrine and paracrine regulation (Letterio and Roberts, 1998). TGFβ signals through TGFβ receptors as a heterodimer, TGFβRI, also called ALK5, and TGFβRII, to activate downstream signaling pathways (Hinck, 2012). Canonical TGFβ signaling involves binding of the ligand to TGFβRI and subsequent dimerization of the TGFβRI and TGFβRII at the cell surface, and then phosphorylation of SMADs (Shi and Massague, 2003) with translocation to the nucleus to induce transcription of downstream targets. TGFβRII, which is not directly part of canonical TGFβR signaling, can impact this pathway as it can bind TGFβ ligands to the cell surface and serve as a reservoir of ligand for signaling. TGFβRIII also has high affinity to the glycoprotein, endoglin, which can also bind TGFβRI and modulate signaling (Gordon and Blob, 2008). TGFβs can activate non-SMAD-dependent signaling pathways (non-canonical pathways), including the mitogen-activated protein kinase (MAPK) pathway mediated by p38, c-Jun amino terminal kinase (JNK), extracellular signal-regulated kinases (ERK), nuclear factor-κB (NF-κB), Rho, phosphatidylinositol 3-kinase (PI3K) (Letterio and Roberts, 1998), and protein kinase B (Akt) (Zhang, 2009), with respective downstream signaling leading to various cellular events. Both canonical and non-canonical pathways are highly species conserved (Massague, 2008).

The therapeutic potential of inhibiting TGFβ signaling has been well characterized with encouraging results in animal models of fibrosis (Gellibert et al., 2006) and cancer (Yoshioka et al., 2011). However, maintaining safety when targeting this pathway can be challenging given the role of TGFβ signaling in homeostatic maintenance of tissues. Earlier work with various TGFβ receptor inhibitors (TGFβRIs) evaluated efficacy in tumor regression/metastasis and fibrosis as well as potential toxicities (Frazier et al., 2007;
Valvular interstitial cells (VICs) are the most prevalent cell type in the heart valve and have context-dependent phenotypes including stem cell-like VICs, osteogenic VICs, myofibroblast-like VICs (also known as activated VICs [aVICs]), and quiescent VICs (qVICs). Together, the multiple phenotypes are responsible for maintaining elasticity, structure, and repair/renewal processes essential in maintaining functional integrity of the valve (Han et al., 2013; Liu et al., 2007). The exquisite interplay among the VIC phenotypes achieves a structure that is flexible enough to change shape easily and strong enough to withstand elevated hemodynamic stress (Schoen, 1997). VIC activation is tightly regulated by cytokines that control their differentiation, proliferation, and migration to the site of tissue remodeling and repair (Powell et al., 1999). In injured or diseased valves, qVICs become aVICs with myofibroblast characteristics including increased α-SMA expression, increased secretion of ECM, and expression of matrix metalloproteinases (MMPs) (Gotlieb et al., 2002). TGFβ is a central mediator that drives fibroblasts to differentiate into myofibroblasts in wound healing, scarring, and fibrosis. Additionally, epithelial-to-mesenchymal transition (EMT) (Walker et al., 2004), which is essential in embryogenesis, tumorigenesis, and fibrosis, is also primarily mediated by TGFβ signaling (Turner et al., 2019; Massague and Chen, 2000). Cells undergoing EMT lose E-cadherin expression and undergo cytoskeletal and morphological changes to become mesenchymal to enable invasion (Thiery et al., 2009).

In this study we evaluated three TGFβRI inhibitors that possessed different potencies in causing valvulopathy in the rat. LY2109761 and BMT-A are dual TGFβRI/RII inhibitors that caused valvulopathy, whereas BMT-B is a selective TGFβRI inhibitor, which did not cause valvulopathy at similar exposures that caused valvular toxicity with the other inhibitors. With these inhibitors, the biological effects of inhibiting TGFβ signaling in VICs were studied to better understand this mechanism of toxicity. We propose that TGFβRII inhibition may impact transcriptional regulation of TGFβ3 and that an interplay between TGFβ2 and TGFβ3 may maintain the proper context-dependent microenvironment, EMT-MET (mesenchymal-to-epithelial transition) homeostasis, and VIC phenotype in the rat, where alteration of this balance could lead to valvulopathy.

RESULTS
Pharmacology and toxicology profiles of the respective TGFβRIs
Three TGFβRIs were evaluated in this study. LY2109761 is a potent dual TGFβRI/RII inhibitor previously evaluated in rat toxicity evaluations and reported to cause valvulopathy (Herbertz et al., 2015; Tan et al., 2009; Maratera, 2009). LY2109761 was used as a benchmark compound to explore optimum dose and necropsy times that would be sufficient to induce and histologically detect valvulopathy, respectively. BMT-A and BMT-B are azaindole, a distinct chemotype from LY2109761. BMT-A is a potent dual TGFβRI/RII inhibitor, whereas BMT-B is a potent, selective TGFβRI inhibitor (Table 1). All three compounds presented no substantial off-target activity but presented similar potency to respective TGFβ receptors (Table 1). BMT-A and BMT-B presented acceptable pharmacokinetic profiles in the rat and were selected for toxicological evaluation.

Sprague-Dawley rats were dosed orally with the respective TGFβRI for 4 days, and hearts were collected on Days 4 and 15 (LY2109761) or Day 14 (BMT-A and BMT-B) and evaluated histologically (Table 1,
Early studies with LY2109761 dosed daily for 4 days indicated that although no valvular histopathology was observed at 4 days, by Day 15 LY2109761 caused valvular changes including thickening of the aortic and atrioventricular valves as reported for this compound and other TGFβRis (Herbertz et al., 2015; Maratera, 2009). Subsequently, the BMT compounds were dosed for 4 consecutive days followed by a 10-day dose holiday before necropsy and heart collection. To this end, treatment with BMT-A also caused similar valvulopathy. Most of the rats treated with 50 mg/kg twice a day (BID) or 150 mg/kg once a day (QD) LY2109761 presented valvulopathy, whereas 50 mg/kg BMT-A caused valvulopathy in all five treated animals (Table 1, Figure 1). In contrast, there was no evidence of valvulopathy in rats treated with up to 50 mg/kg BMT-B, which achieved similar exposures as 50 mg/kg BMT-A (BMT-A: AUC_{last} 180 μM*h versus BMT-B: AUC_{last} 137 μM*h) and were substantially higher than the 150 mg/kg QD LY2109761 treatment, which caused valvulopathy in seven of eight rats (AUC_{last} 63 μM*h) (Table 1). A representative set of atrioventricular valves from a rat treated with LY2109761 and BMT-A are presented in Figure 1 and shows the characteristic myxomatous change (thickening) of the valve leaflets, whereas no myxomatous change was observed in rats treated with BMT-B (Figure 1). Following treatment with TGFβRis, the affected valvular histology included the characteristic thickening of the valve.

### Table 1. Relative binding and in vitro cellular potencies of three TGFβRis compared with rat in vivo exposures and valvular toxicity profiles

| TGFβR inhibitor | Potency TGFβRI kinase filter IC50 μM | Potency TGFβRII kinase filter IC50 μM | Potency NIH3T3 proliferation IC50 μM | Dose (mg/kg/day) | Toxicokinetics (Day 1) | Incidence of rats presenting valvular histopathology |
|-----------------|-------------------------------------|--------------------------------------|-------------------------------------|------------------|------------------------|---------------------------------------------------|
| BMT-A           | 0.01                                | 0.03                                 | 0.79                                | 10 QD            | 5.6                    | 36.3                 | 1/5 |
|                 | 0.012                               | >50                                   | 0.12                                | 10 QD            | 10.7                    | 84.3                 | 0/5 |
| LY2109761       | 0.007                               | 0.073                                 | 0.33                                | 50 BID           | 7                      | 16                   | 5/5 |
|                 |                                     |                                       |                                     | 150 QD           | 11                     | 63                   | 7/8 |

Rat valvular interstitial cells: characterization of cultured cells and morphologies

Rat VICs were harvested and cultured according to previously described methods (Liu et al., 2015) (Figure S1). VICs are stem cell-like and grow through clonal expansion (Figure S1A) and have the potential to differentiate into cells with distinct morphology and functions reminiscent of mesenchymal stem cells (Chen et al., 2009). We have found that sub-culture by scraping maintains mesenchymal-like morphology and by maintaining cells in conditioned media, enables VICs to be cultured up to 11 passages without an obvious decrease in proliferation. There are at least three morphologies of VICs observed in primary cultures: spindle-shaped (Figure S1C), flattened, elongated-shaped (Figure S1D); and round-shaped, of which the last is typical of endothelial cells, which may also be present in the primary cultures (Liu et al., 2015) (Figure S1E). However, the cells did not label positive for the endothelial cell marker, CD-31, suggesting the cultures represented predominantly VICs and not endothelial cells (Figures S1I and S1 J). When each morphology of cell was sub-cloned, the cells returned to their original morphologies, suggesting that the observed morphologies do not represent cells in various stages of differentiation (data not shown). When the cells were labeled with a marker that distinguishes the activated phenotype (myofibroblast marker, α-SMA) from the other VIC phenotypes (using mesenchymal marker, vimentin), all cells were positive for vimentin with some additionally positive for α-SMA (Figures S1F–S1H). This observation aligns with an earlier study that characterized the phenotype of cultured porcine VICs, where 64% of the VICs express α-SMA and 98% expressed vimentin (Witt et al., 2012).

Based on several studies (Liu et al., 2007; Taylor et al., 2003), maintaining VICs in a quiescent state is important for maintaining normal structure and function of the valve, and qVICs are considered to have the closest biology to endogenous VICs in the valve in vivo (Liu et al., 2007). In this study, all the experiments were performed with cultures that promoted mostly qVICs (Figure S1B). This was achieved by serum-starving the cells in culture media containing 0.5% FBS for at least 24 h before treatment, which slowed proliferation. The cells used in the experiments were from passages 3–8. Working with early passages of VICs are optimal in maintaining quiescence, because over several passages, the cultured cells have been reported to become more activated in phenotype (Latif et al., 2006).
TGFβ-mediated signaling is intact in cultured VICs

TGFβ and TGFβR expression in VICs: Transcriptional profiles of TGFβ and TGFβR expression were evaluated in cultured VICs, compared with expression in rat thoracic aorta, another target of TGFβR-induced toxicity, and both assessed relative to rat heart muscle expression (not considered a direct target of TGFβR inhibitor toxicity). As in aorta, VICs transcriptionally expressed all three TGFβ ligands and TGFβ receptors. All TGFβ ligands were robustly expressed in VICs at a range of ~10- to 50-fold higher expression relative to heart. Additionally, TGFβ1 and TGFβ2 were 2-fold and 10-fold higher in VICs than thoracic aorta, respectively, whereas TGFβ3 expression was similar in VICs and thoracic aorta (Figure 2A). In contrast TGFβRI, TGFβRII, and TGFβRIII expression was the highest in thoracic aorta (~5- to 7-fold relative to heart) and expression of TGFβRI and TGFβRII was about 2-fold higher relative to VICs. However, VICs presented low expression of TGFβRIII, which was considerably less relative to heart and aorta (Figure 2B).

TGFβ induced p-SMAD3 activation in VICs: Phosphorylation of SMAD2 and SMAD3 is well characterized in TGFβ-induced EMT. Activation of SMAD3 was demonstrated in VICs with dose-responsive increases in p-SMAD3 protein following hTGFβ stimulation, with peak response in p-SMAD activity within 1 h post stimulation (Figure 2C). The response was sustained for at least 48 h.

TGFβ drives activation of VICs: TGFβ is a central activator of the myofibroblast phenotype and EMT during wound healing processes (Martin, 1997). aVICs are similar to myofibroblasts and express α-SMA and Tagln, maintaining stretch, elasticity, and matrix in the valve using similar processes as those in repair mechanisms (Hosper et al., 2013; Sappino et al., 1990). When VICs were stimulated with 10 ng/mL hTGFβ for 48 h to mimic cell activation, ACTA2 (which encodes α-SMA) and Tagln increased ~2- and ~4-fold, respectively, indicating enhanced activation of VICs (Figure 2D).

TGFβRIs pharmacologically mediate both canonical and non-canonical signaling: TGFβRIs effectively decreased p-SMAD3 in a concentration-dependent fashion, which was achieved with (Figure 2E) or without (Figure 2F) pre-stimulation with hTGFβ. Considering the strong transcriptional expression of TGFβ ligands in these cells, these results suggested that TGFβ signaling is intact and possesses constitutive, autocrine activity. Based on these results, we subsequently performed biological assessments in VICs without pre-stimulation with hTGFβ as a means to better reflect endogenous response to TGFβR inhibition.
To assess whether non-canonical TGFβ signaling may be present in VICs, VICs were treated with a concentration range of TGFβRIs and profiled for p-SMAD2, p-AKT, and p-ERK1/2 (Table 2) and mTOR phosphoproteins (Table S3). All the phosphoproteins were detected in VICs, and all compounds were potent inhibitors of p-SMAD2, with varying potency in inhibiting p-AKT and mTOR phosphoproteins. Only LY2109761 presented inhibitory, albeit relatively weak, activity on p-ERK1/2. Altogether the studies indicate both intact canonical and non-canonical signaling are present in the VICs, but the respective inhibitors may have differential potency in inhibiting phosphoproteins associated with non-canonical signaling.

Early alterations in biological responses to TGFβRI treatment in VICs

TGFβRIs may induce metabolic remodeling: TGFβRIs cause myxomatous changes in valves typically within 1–2 weeks in rats. These changes include increased VIC proliferation and glycosaminoglycan production in
the valve leaflets (Walker et al., 2004). We evaluated the early effects of TGFβRs on cellular proliferation and mitochondrial function of VICs. VICs were treated with TGFβRs for 48 h and evaluated for cytotoxicity, ATP activity, oxidative stress, mitochondrial respiration, and proliferation. The cells were treated at a concentration range of 0.01–10 μM, evaluated for viability by microscopy, then labeled with markers for apoptosis and necrosis, and evaluated by flow cytometry. Following TGFβRI treatment, cells appeared to be growing normally with no obvious impact on viability, which was confirmed by flow cytometry analysis, where there were no changes on percentages of apoptotic or necrotic populations (Table 3 and Table S4). Despite the lack of cytotoxicity, all inhibitors caused concentration-responsive decreases in ATP levels, decreased reactive oxygen species (ROS) production, and decreased mitochondrial respiration (Figures 3A and 3B). Proliferation measured by CyQUANT analysis indicated that TGFβRI treatment caused concentration-dependent decreases in cellular proliferation (Figure 3A). Together these results suggest that early responses of TGFβ signaling inhibition may not involve increased proliferation but repress cellular metabolism, perhaps initiating metabolic remodeling associated with other biological changes (Trefely and Wellen, 2018).

**TGFβRIs alter autocrine TGFβ signaling:** Following 48-h treatment with TGFβRIs, VICs were evaluated for impact on TGFβ receptor/ligand gene expression. TGFβRIs decreased TGFβ signaling including concentration-related inhibition of p-SMAD and decreased transcription of all TGFβ ligands and TGFβRII expression (Figure 4A). In contrast, TGFβRIs upregulated TGFβRII and TGFβRIII expression, the latter with a remarkable ~8- to ~30-fold upregulation in expression, which may have been a compensatory response to the depletion of ligand expression. Although all three inhibitors presented similar responses, the only exception was that TGFβ3 transcriptional expression remained unaltered following BMT-B treatment.

**TGFβRIs alter ECM production from VICs:** Elastin fiber disruption in the heart valves and aorta has been associated with TGFβ inhibitor treatment (Anderton et al., 2011; Rak et al., 2020). TGFβ has also been found to stimulate transcriptional expression of elastin (ELN) (Kahari et al., 1992). All inhibitors effectively decreased ELN transcription in a concentration-related manner (Table 4 and Figure S2). Additionally, the transcriptional expression of the collagens that comprise ~90% of ECM protein in the heart valve, COL 1A1 and COL 11A1, were decreased (Table 4 and Figure S2) (Wiltz et al., 2013; Hosper et al., 2013; Vazquez-Villa et al., 2015). On a protein level, collagens were likewise decreased following TGFβRI treatment (represented with LY2109761 in Figure 4B). In contrast, elastin protein levels presented concentration-related increases with LY2109761 and BMT-A treatment but mild decrease with BMT-B treatment (Figure 4B).

**TGFβRIs alter VIC phenotypes:** All TGFβRIs caused concentration-dependent decreases in ACTA2 and Tagln and increased E-cadherin transcription, a marker of epithelial cells (Frixen et al., 1991) (Figure S2), suggesting that the VIC phenotype may be changing toward an epithelial phenotype, such as observed in MET. The mesenchymal marker, vimentin, along with MMP2, an EMT inducer, presented mild transcriptional up-regulation (ranging up to 2.5× at 10 μM), but this was not as pronounced as the down regulation of the myofibroblast markers (Table 4, Figure S2, Table S5) (Cheng and Lovett, 2003). These responses may reflect a potential imbalance of EMT/MET because EMT/MET are multi-step reciprocal processes with cells in different phases of differentiation, where some cells may be more advanced in transitioning toward epithelial transition, whereas others are more mesenchymal (Willis and Borok, 2007).

VICs were labeled with antibodies against protein markers of αVICs (α-SMA<sup>high</sup>/vimentin<sup>+</sup>) versus other VIC phenotypes (α-SMA<sup>low</sup>/vimentin<sup>+</sup>) and evaluated by confocal microscopy to better characterize the effects of the transcriptional changes on VIC phenotypes, cytoskeletal architecture, and morphology. LY2109761 and BMT-A caused concentration-dependent changes in cellular morphology and labeling pattern, where α-SMA<sup>high</sup>-positive cells presented progressively disorganized actin filaments, whereas vimentin patterns remained unchanged or were slightly more pronounced (Figure 5A). In contrast, BMT-B appeared to have

---

**Table 2. IC50 (μM) of phosphoprotein expression at 48 h post TGFβRI treatment**

| TGFβR inhibitor | p-Akt | p-ERK1/2 | p-Smad2 |
|----------------|-------|----------|--------|
| LY2109761      | 0.42 ± 0.08 | 2.08 | 0.04 |
| BMT-A          | 0.13 ± 0.05 | >10 | 0.02 ± 0.01 |
| BMT-B          | 0.85 ± 0.31 | >10 | 0.14 ± 0.03 |

SEM represents the average of four experiments with the exception of p-ERK1/2 (all compounds) and p-SMAD2 (for LY2109761), which were only run once.
less effect on cellular morphology and α-SMA/vimentin staining. Following TGFβRi treatment, cell impedance was additionally assessed over a time course. Impedance will change as cells proliferate, become more adherent, or undergo morphological changes. Cellular impedance increased in DMSO-treated control VICs but presented concentration-related decrease with LY2109761 and BMT-A treatments. In contrast, there was minimal change in impedance with BMT-B (Figure 5B), suggesting that BMT-B had less of inhibition of adhesion and morphological change.

VICs treated with 10 μM of each TGFβRi were evaluated by flow cytometry with antibodies against α-SMA and vimentin. The relative brightness of α-SMA and vimentin staining would indicate whether VICs may be becoming more activated in phenotype. BMT-A treatment caused a slight increase in intensity of α-SMA staining, whereas there was no notable change in staining intensity following treatment with LY2109761 and BMT-B. All compounds caused an increase in vimentin staining intensity, agreeing with the observed increased transcriptional expression of vimentin that suggested an alteration of EMT-MET balance. VICs were additionally stained with antibodies against epithelial markers, EpCAM, E-cadherin, and the endothelial marker, CD-31. VICs normally do not express these markers, and following TGFβRi treatment they remained negative for staining by both flow cytometry and immunohistochemical evaluation (data not shown). This indicated that the VICs were not definitively changed into an epithelial or endothelial phenotype (Figure S3).

Considering the morphological changes and alteration of EMT/MET markers, a scratch test was undertaken to determine whether TGFβRi treatment altered cell migration (Liang et al., 2007). Following preparation of VIC cultures, a scratch was made in the middle of the well followed by administration of 10 μM TGFβRi. Three wells per treatment were photographed at 0, 6, 24, and 48 h post scratch, where photographs were taken at the same marked location. The annotation of the scratched open area was performed for the 0 h image, and then the annotation was copied and pasted for its sequential images at 6, 24, and 48 h. Thus, the area of the cells was measured and the percentage of cell density was calculated and compared to the Time 0 (T0) density. DMSO and BMT-B treatments showed similar and significant increases in cell density in the scratch region over the entire time course, suggesting cell migration was intact. In contrast, both LY2109761 and BMT-A did not present significant migration at the 6 h time point and reduced migration at 24 and 48 h, suggesting that migration was inhibited with these treatments (Figure 5C).

TGFβ2 and TGFβ3 may mediate signaling involved in maintaining VIC phenotype

In context of the finding that TGFβ ligands were robustly transcribed in VICs and VICs present autocrine signaling, small interfering RNA (siRNA) experiments were undertaken to determine whether loss of function of specific ligands may produce similar biological changes as observed with the inhibitors. Multiple siRNA constructs for each respective ligand were evaluated in rat VICs to identify constructs with low toxicity and high specificity to the respective ligands (Figure S4A). During the course of these evaluations, it was found that multiple constructs directed against rat TGFβ2 or TGFβ3 caused decreased transcription of both ligands in VICs despite lack of homology of the respective constructs to other TGFβ sequences (Figures 6A and S4A). Together this suggested that transcriptional expression inhibition of either ligand may influence transcriptional regulation or mRNA stability of TGFβ2 or TGFβ3.

Silent RNA knockdown of TGFβ1 had no significant effect on transcription of myofibroblast targets or Col1A1, whereas knockdown of TGFβ2 or TGFβ3 caused decreases in expression of ACTA2, Tagln and Col 1A1, and ELN that were similar to responses observed with TGFβRis (Figures 6B and S4B).

Owing to the co-down regulation of TGFβ2/β3 transcriptional expression observed with the TGFβ2 or β3 siRNA constructs, it was unclear from the siRNA experiments whether either or both ligands mediated

| µM  | % of Dead Cells | % of Apoptosis |
|-----|----------------|---------------|
| 0   | 4.4            | 1.4           |
| 0.01| 3.0            | 0.6           |
| 0.1 | 3.9            | 1.1           |
| 1   | 3.7            | 1.3           |
| 10  | 2.6            | 0.7           |

Table 3. Flow cytometric analysis of apoptosis and necrosis of VICs at 48 h following LY2109761 treatment
these responses. However, the finding that TGFβ3 transcriptional expression was unaltered following treatment with the non-valvular toxic TGFβRI (BMT-B), suggested the need for further evaluation of potential roles of these ligands in maintaining VIC phenotype.

To this end, VICs were treated with a pan-TGFβ neutralizing antibody, 1D11, previously demonstrated to cause valvulopathy in the rat (Martin et al., 2020). Additionally, VICs were also treated with TGFβ ligand-specific neutralizing antibodies to determine impact on secreted TGFβs, p-SMAD signaling, and transcription of phenotypic markers.

Initially, VICs were treated with a concentration range of respective neutralizing antibody and evaluated for p-SMAD3 inhibition at 1 and 48 h post treatment. At 10 μg/mL, all antibodies inhibited p-SMAD3, which was detectible by 1 h and retained effective inhibition at 48 h (Table 5). Therefore an antibody concentration of 10 μg/mL was selected to evaluate effects of ligand neutralization on VIC phenotype.

Figure 3. TGFβRi treatment alters mitochondrial function and cell proliferation in VICs
(A) Assessment of mitochondrial function and cell proliferation following 48-h treatment with TGFβRi inhibitors. Mitochondrial function was measured by ATP production, oxidative stress (ROS generation), and cellular mitochondrial respiration. Proliferation was evaluated by CyQUANT. Concentration-responsive decreases in production of ATP and ROS and proliferation were observed following TGFβRi treatment.
(B) Cellular mitochondrial respiration evaluation by Seahorse. Additional evaluation of mitochondrial respiration with LY2109761 following 48-h treatment demonstrated concentration-related decreases, which was also observed with other TGFβRi inhibitors (data not shown).
Represented data are the average of three experiments ±SEM. Statistical comparisons employed one-way or two-way ANOVA followed by Dunnett’s test. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.005; ****p ≤ 0.0001.
TGFβ1, 2, and 3 was measured in cell culture media (starving media containing 0.5% FBS in M199) as well as conditioned media following 5 days of VIC culture. The conditioned media represents the 3 days VICs are cultured in serum-starved conditions plus the 2 days duration for running TGFβRi experiments. Rat serum was used as a positive control for confirming measurement of each respective ligand (Table 6). Because the cell culture media contained 0.5% FBS, the media was measured for respective ligand to determine background levels. The cell culture media contained low levels of TGFβ1 and TGFβ2 representing approximately 18% and 1% of the levels measured in conditioned media, respectively. There was no detectible TGFβ3 measured in the cell culture media or conditioned media (Table 6).

Following 48-h treatment with TGFβ neutralizing antibodies, the pan-neutralizing antibody-depleted TGFβ1 and TGFβ2 levels were 45% of vehicle control. The TGFβ1- and TGFβ3-specific antibodies attenuated (<50% reduction) TGFβ1 and TGFβ2 protein levels. However, the TGFβ2 neutralizing antibody reduced TGFβ2 levels to 26% of control but only attenuated TGFβ1 levels. Combination of TGFβ2 + TGFβ3 neutralizing antibodies

Figure 4. TGFβRi treatment alters TGFβ receptor, ligand, and ECM expression in VICs

(A) Comparison of transcriptional changes of TGFβ ligands and receptors in VICs following 48-h treatment with TGFβRIs. All inhibitors caused similar transcriptional alterations of ligand and receptor expression with the exception of BMT-B, which caused less increase in TGFβRII and TGFβRIII transcription and had no inhibitory response on TGFβ3 transcription.

(B) Effect on collagen production in VICs following 48-h treatment (represented with LY2109761).

(C) Elastin protein production increased following LY2109761 and BMT-A treatment but decreased following treatment with BMT-B.

For each transcriptional target, at least three TGFβRi-treated VIC samples were analyzed with two technical replicates (≥6 PCR tests) in calculating ± SEM. For the protein measurements, represented data are the average of three experiments ± SEM.
had no effect on TGFβ1 levels and caused a similar reduction of TGFβ2 as observed with the TGFβ2 neutralizing antibody, suggesting TGFβ3 protein neutralization had no additive or synergistic impact on reducing ligand levels (Table 6).

The effects of 48-h 10-μM treatments with LY2109761 and BMT-B on TGFβ ligands were additionally evaluated, and both inhibitors had similar impact on reducing TGFβ1 and TGFβ2 as the TGFβ2 neutralizing antibody (Table 6).

At 48 h following TGFβ neutralizing antibody treatment, VICs were collected and evaluated for transcriptional changes of phenotypic markers. Interestingly, 1D11 significantly reduced the transcription of myofibroblast and ECM targets and increased TGFβ3 transcription. In contrast, TGFβ3 neutralizing antibody treatment only significantly increased TGFβ3 transcriptional expression, whereas TGFβ2 neutralizing antibody treatment caused significant but slight decreases in Tagln and ELN and a slight increase in TGFβ3 expression. However, co-treatment with TGFβ2 and TGFβ3 neutralizing antibodies resulted in similar changes as 1D11 (Table 7).

**DISCUSSION**

**Potential mechanisms of toxicity associated with TGFβR inhibition in VICs**

VICs exhibit a constitutive level of p-SMAD activity and respond robustly to TGFβ stimulation, and they do not need pre-stimulation with ligand to assess inhibition of canonical signaling with the TGFβR inhibitors due to TGFβ synthesis and secretion in VICs. These findings, together with confirmation that the VICs express all three TGFβ ligands and receptors, suggest that the TGFβ signaling is constitutively active and the cells have autocrine regulation of this pathway. Very few cell types have shown constitutive p-SMAD expression. Instead, most cells/tissues require pre-stimulation with TGFβ ligand before measurement of inhibitory activity. Interestingly, the exceptions encountered in our hands have been tumor cells/tissue, vascular aortic smooth muscle cells/aortic tissue, and heart valves/VICs (data not shown). It is possible that the dependency of these cell types/tissues on constitutive TGFβ signaling may be the basis for why tumor efficacy and the cardiovascular toxicity tend to occur at similar exposures, making safety windows very narrow or non-existent.

The biological response of TGFβ signaling depends on the cell type and microenvironment. TGFβ could either promote or suppress cancer progression and metastasis depending upon the context of the tumor type and associated microenvironment (David and Massague, 2018; Stover et al., 2007). In the heart valve,
TGFβ will promote VIC proliferation in response to injury, but when VICs are cultured in low-density monolayers without TGFβ stimulation and other growth factors, there is decreased proliferation, independent of injury (Li and Gotlieb, 2011). In vivo, treatment of rats with TGFβRIs produced valvulopathy that included VIC proliferation (Frazier et al., 2007; Anderton et al., 2011). However, treatment of cultured VICs with TGFβRIs, reduced proliferation compared with vehicle controls. Proliferative response was profiled in vitro over a 48-h period, whereas the proliferation response observed in vivo was typically not histologically apparent until ~1–2 weeks post initial dose. Similar observations have been reported with cultured VICs treated with TGFβRIs, highlighting the importance of in vitro models for studying VIC proliferation in a controlled environment.
porcine VICs treated with the TGFβRI inhibitors, SB431542 and SD208, which resulted in concentration-dependent decreases in VIC proliferation and had no effect on apoptosis (Li and Gotlieb, 2011). TGFβ can induce ROS production and suppress antioxidant response inducing oxidative stress or redox imbalance (Liu and Desai, 2015; Weidinger and Kozlov, 2015). Although the VICs presented relatively unaffected proliferation and viability following TGFβRI treatment, there was a concentration-dependent decrease in mitochondrial respiration, ATP production, and ROS generation within 48 h, suggesting lack of oxidative stress but possible alteration in mitochondrial function that included decreased energy production without cytotoxicity. This response may be possibly related to a change in VIC phenotype and function, which may require cellular metabolism shifts and other biological changes similar to those encountered in differentiation response (Trefely and Wellen, 2018).

During injury or abnormal hemodynamic/mechanical stress, local accumulation of cytokines and growth factors, including TGFβ, will stimulate qVICs to change to an activated, myofibroblast-type cell, expressing α-SMA and producing increased ECM, which engages in repair mechanisms (Elangbam, 2010). Increased numbers of VICs were observed in valves of rats treated with TGFβRI inhibitors and have altered morphology that have changed from fibroblast-like to more rounded morphology as well as increased presence of glycosaminoglycans in the surrounding matrix (Anderton et al., 2011) (Figure 1). Following TGFβRIi treatment, cultured VICs presented similar changes in shape as well as decreased collagen and elastin transcription. Although collagens were also decreased on a protein level, interestingly, elastin production increased with the valvular toxic TGFβRIs but not with BMT-B. Elastin is a direct transcriptional target of TGFβ signaling, where TGFβ affects both elastin transcription and mRNA stability (Davidson,
Table 5. Percentage of p-SMAD3 activity relative to PBS controls at 1 and 48h post TGFβ neutralizing antibody treatment

| Treatment | 1D11 | Anti-TGFβ1 | Anti-TGFβ2 | Anti-TGFβ3 | Anti-TGFβ2+3 |
|-----------|------|------------|------------|------------|-------------|
| 1 h       | 37 ± 6.85****  | 66.9 ± 6.45*  | 63.89 ± 7.55*  | 77.48 ± 11.31 | 102.29 ± 10.72 |
| 48 h      | 32.58 ± 6.38****  | 66.45 ± 13.57*  | 42.93 ± 7.65****  | 46.54 ± 3.13****  | 39 ± 8.96****  |

Average of three experiments ± SEM; 10 µg/mL neutralizing antibody used in respective treatments. Statistical comparisons employed one-way or two-way ANOVA followed by Dunnett’s test. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.005; ****p ≤ 0.0001

2002), Elastin is translated into a precursor protein, tropoelastin, which was the form of elastin that was measured in our assessment. Tropoelastin together with fibulin-5 deposits onto microfibrils in elastin fiber assembly (Noda et al., 2013), and disruption of elastin filament organization in heart valves and aorta is commonly identified with the histopathology of TGFβR inhibitors and animals/humans possessing inactivation mutations. The increased tropoelastin production associated with LY2109761 and BMT-A may reflect a compensatory response to alteration in elastin mRNA levels but will likely decrease with sustained TGFβR inhibition. It is possible that the less potent phenotypic changes observed following BMT-B treatment may also reflect less impact on elastin transcription and tropoelastin production leading to less effect on downstream elastin fiber assembly.

The interaction between elastin and collagens is critical to valvular function. Elastin is mechanically coupled to collagen and important in maintaining specific collagen fiber configuration for imposing tensile forces on collagen fibers during valve unloading. Furthermore, it is important in restoring collagen fiber geometry back to resting confirmation between loading cycles (Vesely, 1998). Additionally, glycosaminoglycans bind to the collagens, altogether making up a delicately balanced ECM that must maintain appropriate levels of stiffness and elasticity to withstand constant sheer stress, expansion, and contraction associated with the load cycle.

Additional changes occurred suggesting phenotypic change, particularly with the valvular toxic TGFβRis, LY2109761 and BMT-A. These included alterations of the active VIC phenotype including decreased myofibroblast marker transcription along with increases in MMP2, vimentin, and E-cadherin expression. Phenotypic changes were further supported by assessment of α-SMA protein organization, where following TGFβRi treatment, there was disruption of the striated α-SMA filament pattern with associated rounded or tile-like morphological changes along with decreased cellular impedance, indicative of reduction in cell-cell adhesion. Furthermore, the valvular toxic inhibitors presenting reduced cell migration in the scratch test indicates that the cellular responses were associated with altered EMT-MET homeostasis. This suggests that TGFβRis have a direct effect on the balance of avICs and other VIC phenotypes without influence from exogenous cytokines or inflammatory processes. Inhibition of TGFβ signaling may drive the VICs toward MET resulting in phenotypic and functional alterations that could have a damaging effect on the integrity of the valve in vivo. Altogether, the TGFβRi-induced valvular toxicities observed in the rat may be due to deregulation and possible switching of the aVIC phenotype to other phenotypes that lose stretch and elasticity and homeostatic repair/renewal mechanisms associated with response to hemodynamic shear and mechanical stress.

Maintenance of TGFβ3-mediated signaling may be protective against TGFβRi-induced valvulopathy

Small-molecule TGFβRis have been reported to cause valvulopathy in nonclinical toxicity species (Anderson et al., 2011; Frazier et al., 2007; Stauber et al., 2014), and we have additionally encountered similar toxicities in the rat with BMT-A and LY2109760. Given this precedence and the similarity of these toxicities to rodent and human inactivation mutations affecting the TGFβ signaling pathway, it is likely that these toxicities are pharmacologically mediated. A difference between small molecules is that the class-based toxicities can occur at different exposures, and sometimes the toxicity can be mitigated by inclusion of dose holidays in the administration schedule (Stauber et al., 2014). In our experience, we found that BMT-B did not cause cardiovascular toxicity within exposure ranges that effectively produced valvular toxicity with LY2109761 and BMT-A, even though all three TGFβRis were similar in TGFβRi binding and biological potencies. As such, we compared the effects of the inhibitors on biological response in cultured VICs to determine if there were any differences that may relate to the lack of valvular toxicity associated with BMT-B.
Although the three inhibitors induced some similar biological responses, a striking difference was identified with TGFβ3 expression profiles following TGFβRI treatment. All three inhibitors caused mild reduction of TGFβ1 and TGFβ2 transcriptional expression. However, only the valvular toxicants, LY2109761 and BMT-A, caused potent and steep concentration-dependent reduction of TGFβ3 transcription, whereas BMT-B treatment had no effect on TGFβ3 expression. Importantly, BMT-B presented less effects on phenotypic change of VICs compared with the valvular toxic inhibitors, suggesting that sparing TGFβ3 may protect the VICs from these alterations.

Furthermore, both the siRNA and TGFβ neutralizing antibody studies demonstrated that combined loss of function of TGFβ2 and TGFβ3 on an RNA or protein level caused similar transcriptional changes indicative of EMT-MET imbalance and altered ECM, implying them as the primary ligands driving TGFβ signaling for maintaining appropriate context-dependent phenotype of VICs. In addition, the observed co-reduction in TGFβ2/β3 transcription associated with TGFβ2 or β3 RNA silencing suggests potential existence of transcriptional co-regulation or regulation of mRNA stability of these ligands.

Only TGFβ1 and TGFβ2 were secreted at detectable levels from VICs, where the valvular toxic pan-neutralizing antibody, 1D11, effectively depleted TGFβ1 and reduced TGFβ2 levels by ~75%. The TGFβ2 neutralizing antibody had a similar effect on reducing TGFβ2, whereas the TGFβ3 antibody administered alone or in combination with the TGFβ2 antibody had considerably less inhibitory effect on TGFβ2 levels. However, combination treatment of TGFβ2 and TGFβ3 neutralizing antibodies synergized transcriptional deregulation of phenotypic markers and increased TGFβ3 transcription, indicating that both ligands have important involvement in this mechanism. In VICs, TGFβ2 appears to be the prominent secreted ligand responsible for driving signaling involved in maintaining the VIC phenotype. However, our studies also suggest that TGFβ3 may also have a role in this biology. It is possible that TGFβ3 function is more relevant on the cellular level where its transcriptional regulation can impact transcription of TGFβ2 and associated feedback mechanisms. It is also possible that its protein may be expressed at low levels and kept in reserve on the cell membrane via TGFβIII for signaling purposes.

| Table 6. Amount of TGFβ ligands present in rat serum and VIC media and effect of 48-h TGFβ neutralizing antibody or TGFβRI treatment on secreted ligands into VIC media |
| TGFβ1 (pg/mL) | TGFβ2 (pg/mL) | TGFβ3 (pg/mL) |
|----------------|----------------|----------------|
| Control (pg/mL) | | | |
| Rat serum | 5302.8 ± 191 | 3336.7 ± 93 | 187.5 ± 11.3 |
| Media alone (0.5% FBS/M199)* | 624.5 ± 20.3 | 22.21 ± 2.3 | <BDL |
| Conditioned media** | 3558 ± 61.3 | 1676.6 ± 56.8 | <BDL |
| Neutralization antibodies (percentage of control 3) | | | |
| PBS control | 100 | 100 | <BDL |
| 1D11 (10 μg/mL) | ≤0 | 45 | NA |
| TGFβ1 (10 μg/mL) | 57.4 | 72.5 | NA |
| TGFβ2 (10 μg/mL) | 77.4 | 26.4 | NA |
| TGFβ3 (10 μg/mL) | 65.5 | 51.5 | NA |
| TGFβ2+TGFβ3 (10 μg/mL each) | 100.1 | 29.9 | NA |
| TGFβRIs (percentage of control 4) | | | |
| DMSO* | 100 | 100 | <BDL |
| LY2109761 (10 μM) | 55 | 27.5 | NA |
| BMT-B (10 μM) | 59 | 31.9 | NA |

<BDL, below detectible level; NA, not applicable due to lack of detectable ligand in cell media. Average of three experiments ± SEM.

*Baseline TGFβ concentration was measured with pre-test culture media containing 0.5% FBS in M199.
**PBS in 0.5% FBS/M199 was used as an experimental control for VICs treated with TGFβ neutralizing antibodies. The amount of TGFβ in these samples reflects 4–5 days’ accumulation (seeding + starving).
1.0% DMSO in 0.5% FBS/M199 is used as an experimental control for VICs treated with TGFβRIs.
| Percent change calculation: (actual concentration – media alone/control concentration (PBS or DMSO)) × 100. |
It is unclear why BMT-B presented the distinct profile where it had no effect on inhibiting TGFβ3 transcription and possessed lack of valvular toxicity at relatively high exposures. All three inhibitors presented similar potencies on TGFβRI, yet BMT-B generally was the least potent in altering the profiled biological responses. BMT-B and BMT-A are both azaindoles with only slight differences in chemical structure (Fink et al., 2017; Zhang et al., 2018). However, unlike LY2109761 and BMT-A, BMT-B is a selective TGFβRI inhibitor with no significant activity on the TGFβRII receptor. In contrast, both LY2109761 and BMT-A were potent dual receptor inhibitors with ≤10 fold selectivity on TGFβRI over TGFβRII, respectively. Given overall preclinical experience evaluating both dual and TGFβRI-selective (ALK5) inhibitors, both pharmacological classes will likely cause valvulopathy as dose and/or duration of treatment increases. Interestingly, the only TGFβR inhibitors currently in clinical development are selective TGFβRI inhibitors, which require dose holidays to achieve an acceptable but narrow safety window for avoiding cardiovascular toxicity (Herbertz et al., 2015; Keedy et al., 2018; Rak et al., 2020).

TGFβ1 and TGFβ3 bind to TGFβRII to initiate RI/RII dimerization and canonical signal transduction and may include feedback mechanisms as indicated in this study. It is possible that transcriptional regulation of TGFβ3 is dependent upon TGFβRII signaling and that the lack of inhibitory activity of BMT-B on TGFβRII allowed appropriate feedback signaling for maintaining TGFβ3 transcription. Alternately, the selective TGFβRI inhibitory activity of BMT-B might have allowed for non-canonical signaling mediated by TGFβ1 and TGFβ3 that was not dependent upon TGFβRII activation. All three of the TGFβRIs presented inhibitory activity on p-AKT; however BMT-B had the least potent inhibitory activity. Activation of AKT is associated with regulation of TGFβRII, where it causes phosphorylation of p-FAF1, which leads to decreased cell surface FAF1 and an increase of TGFβ3 expression (Xie et al., 2017). The more potent inhibitory activity of BMT-A and LY2109761 on p-AKT, together with direct inhibitory activity on TGFβRII, may have further repressed feedback regulation of TGFβ3 expression.

Additionally, TGFβRII expression levels have been found to impact both SMAD and non-SMAD signaling pathways and alter biological effects of TGFβ signaling (Rojas et al., 2009). For instance, activation of the MAP/ERK pathway is dependent upon TGFβRII (Rojas et al., 2009). The MAP/ERK pathway has been implicated in calcification processes, and ERK1/2 is upregulated in VICs cultured in conditions promoting calcification processes (Gu and Masters, 2010). Activation of ERKs are also implicated in valvulopathy caused by 5-hydroxytryptamine receptor 2B (5-HT2B) receptor agonists, where ERK activation occurs as part of the 5-HT2B receptor signaling cascade and leads to mitogenic responses in the heart valve (Elangbam, 2010). Serotonin can enhance the activity of TGFβ receptors, suggesting an intersection between the two pathways (Elangbam, 2010). However, inhibition of TGFβRII would be thought to down regulate ERK signaling with less detrimental effects on the heart valve. Only LY2109761 presented weak inhibitory activity on p-ERK1/2 in VICs (Table 2) and did not show any protective activity on altered biological responses in the VICs or valvulopathy in the rat in vivo. Further work will be required to better understand the underlying basis for how BMT-B maintained TGFβ3 transcriptional expression and how TGFβ3-mediated signaling protects the VICs from responses that lead to valvulopathy.

| Genes   | 1D11a | Anti-TGFβ2+3b | Anti-TGFβ1b | Anti-TGFβ2b | Anti-TGFβ3b |
|---------|-------|---------------|-------------|-------------|-------------|
| ACTA2   | 0.79 ± 0.03** | 0.79 ± 0.05*  | 1.12 ± 0.03 | 0.92 ± 0.03 | 1.00 ± 0.04 |
| Tgfβn   | 0.88 ± 0.01**** | 0.92 ± 0.04** | 0.97 ± 0.02 | 0.95 ± 0.02* | 0.97 ± 0.02 |
| Col1A1  | 0.90 ± 0.05*   | 0.87 ± 0.08  | 1.11 ± 0.03 | 1.04 ± 0.03 | 1.07 ± 0.07 |
| ELN     | 0.37 ± 0.01**** | 0.71 ± 0.01*** | 1.14 ± 0.05 | 0.86 ± 0.02* | 0.91 ± 0.03 |
| TGFβ1   | 0.88 ± 0.03*   | 0.92 ± 0.08  | 0.97 ± 0.03 | 0.95 ± 0.04 | 0.97 ± 0.04 |
| TGFβ2   | 0.87 ± 0.03**  | 0.91 ± 0.06  | 1.02 ± 0.04 | 1.05 ± 0.04 | 1.11 ± 0.04 |
| TGFβ3   | 1.50 ± 0.04**** | 1.10 ± 0.04  | 1.00 ± 0.03 | 1.18 ± 0.04* | 1.23 ± 0.04* |

Average of three experiments ± SEM. Statistical comparisons employed one-way or two-way ANOVA followed by Dunnett’s test. The values in bold indicate statistically significant transcriptional changes compared to vehicle control.

*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.005; ****p ≤ 0.0001.

1D11 previously demonstrated to cause valvulopathy in rats.

VICs were treated with 10 μg/mL of respective TGFβ neutralizing antibody.

It is possible that transcriptional regulation of TGFβ3 is dependent upon TGFβRII signaling and that the lack of inhibitory activity of BMT-B on TGFβRII allowed appropriate feedback signaling for maintaining TGFβ3 transcription. Alternately, the selective TGFβRI inhibitory activity of BMT-B might have allowed for non-canonical signaling mediated by TGFβ1 and TGFβ3 that was not dependent upon TGFβRII activation. All three of the TGFβRIs presented inhibitory activity on p-AKT; however BMT-B had the least potent inhibitory activity. Activation of AKT is associated with regulation of TGFβRII, where it causes phosphorylation of p-FAF1, which leads to decreased cell surface FAF1 and an increase of TGFβ3 expression (Xie et al., 2017). The more potent inhibitory activity of BMT-A and LY2109761 on p-AKT, together with direct inhibitory activity on TGFβRII, may have further repressed feedback regulation of TGFβ3 expression.

Additionally, TGFβRII expression levels have been found to impact both SMAD and non-SMAD signaling pathways and alter biological effects of TGFβ signaling (Rojas et al., 2009). For instance, activation of the MAP/ERK pathway is dependent upon TGFβRII (Rojas et al., 2009). The MAP/ERK pathway has been implicated in calcification processes, and ERK1/2 is upregulated in VICs cultured in conditions promoting calcification processes (Gu and Masters, 2010). Activation of ERKs are also implicated in valvulopathy caused by 5-hydroxytryptamine receptor 2B (5-HT2B) receptor agonists, where ERK activation occurs as part of the 5-HT2B receptor signaling cascade and leads to mitogenic responses in the heart valve (Elangbam, 2010). Serotonin can enhance the activity of TGFβ receptors, suggesting an intersection between the two pathways (Elangbam, 2010). However, inhibition of TGFβRII would be thought to down regulate ERK signaling with less detrimental effects on the heart valve. Only LY2109761 presented weak inhibitory activity on p-ERK1/2 in VICs (Table 2) and did not show any protective activity on altered biological responses in the VICs or valvulopathy in the rat in vivo. Further work will be required to better understand the underlying basis for how BMT-B maintained TGFβ3 transcriptional expression and how TGFβ3-mediated signaling protects the VICs from responses that lead to valvulopathy.
In summary, we have characterized TGFβ signaling in cultured rat VICs and have used this model to better understand the impact of inhibition of this pathway on biological function of these cells. We have found that blockade of TGFβR signaling results in EMT-MET imbalance, impacting morphology and function, and that TGFβ2 and TGFβ3 may mediate TGFβ signaling in VICs necessary to maintain appropriate context-dependent phenotypes. The TGFβRI, which did not produce valvulopathy at the evaluated dose/exposures, was more resistant to the EMT-MET imbalance and ECM-related changes and did not alter TGFβ3 expression, suggesting that the degree of these responses may potentially predict potency in inducing valvulopathy in vivo. Taken together, these results suggest that the pathogenesis of TGFβRI-induced valvular toxicities may involve redirection of the context-dependent VIC phenotype and impede homeostatic processes essential for maintaining integrity of the valve, where potency of an inhibitor in driving phenotypic change may reflect its potential to cause valvulopathy in vivo.

**Significance of the study**

TGFβR inhibitors (TGFβRis) have promise for treating cancer and fibrotic diseases, but can cause cardiovascular toxicity including valvulopathy in preclinical species, leading to capping of clinical doses or impede progression to the clinic. Although dose-holiday schedules sometimes mitigate toxicity, safety margins remain narrow. VICs can change phenotype pliable based upon the context of their anatomical location and microenvironment in the valve; maintain appropriate elasticity and ECM production; and engage in repair mechanisms essential in maintaining integrity of the valve. VICs express TGFβRis and are suspected to be the cellular target of toxicity of TGFβRis. Using VICs harvested from rats, a sensitive species to TGFβRi -induced valvular toxicity, this study provided additional insight into the mechanism of toxicity. Canonical and non-canonical signaling are intact in VICs. TGFβ ligands are expressed with SMAD2/3 presenting phosphorylation without stimulation, suggesting that TGFβ signaling is constitutive. TGFβRi treatment inhibited transcription of myofibroblast and ECM targets, induced E-cadherin transcription, and altered smooth muscle actin organization, resulting in changes in morphology, cellular impedance, and migration. Together these changes suggest that TGFβR inhibition alters EMT-MET homeostasis in VICs. Additionally, using siRNA and TGFβ neutralizing antibodies, the results suggest that TGFβ2 and-3 may mediate signaling essential for maintaining appropriate balance of context-dependent VIC phenotype within the valve. Altogether these findings provide additional understanding regarding which ligands are essential in mediating TGFβ signaling in VICs and the mechanism of toxicity of TGFβRis and how the pathway could be probed to potentially reduce the potential for valvulopathy.

**Limitations of the study**

VICs present context-dependent phenotypes based upon their anatomical location, microenvironment, and mechanical stresses in the valve. Multiple VIC phenotypes are important to maintain appropriate elasticity and ECM production and engage in repair mechanisms essential in maintaining integrity of the valve. The in vitro approaches used in this study do not fully model the diverse microenvironments and physiological stresses encountered in vivo; however the model demonstrates how the biology of VICs maintained in a static condition can be altered by interference of TGFβ signaling. Also, we have demonstrated that TGFβ2 and TGFβ3 have roles in driving VIC biology; however, we could only demonstrate detectable levels of secreted TGFβ2 protein. This may be related to limitations in sensitivity of detection of the secreted protein with Lumixen technology, that TGFβ3 protein may have its functional relevance on the cellular membrane in association with TGFβ receptors (including TGFβRIII), or in a different microenvironment or under different physiological stresses, TGFβ3 may have more robust expression. Further study will be required to better characterize this function.

**Resource availability**

**Lead contact**

Karen Augustine-Rauch, Department of Discovery Toxicology, Bristol-Myers Squibb, Route 206 & Province Line Road, F1.4107B, Princeton, NJ 08543; E-mail: karen.augustine@bms.com; Ph: 609-252-3089.

**Materials availability**

This study did not generate unique reagents. However, all protocols associated with the work are available upon request. In addition, BMT-A and BMT-B are not available due to limited supply of synthesized compound. However, these azaindole series inhibitors can be synthesized according to information provided in Zhang et al. (2018). The structure of BMT-A and BMT-B can be found as Example 14B and 47, respectively, in Fink et al., (2017), Patent US 9,708,316 B2.
Data and code availability
The raw datasets supporting the current study have not been deposited in a public repository due to our company’s information protection policies but are available from the corresponding author upon requests.

METHODS
All methods can be found in the accompanying Transparent methods supplemental file.

INCLUSION AND DIVERSITY
We worked to include sex balance in the selection of non-human subjects. The author list of this paper includes contributors from the location where the research was conducted who participated in the data collection, design, analysis, and/or interpretation of the work.

SUPPLEMENTAL INFORMATION
Supplemental information can be found online at https://doi.org/10.1016/j.isci.2021.102133.

ACKNOWLEDGMENTS
We thank Miguel Sanjuan, Myrtle Davis, and Greg Rak for their critical review of the manuscript. We are grateful to Steven Stryker, Yimer Callejas, Karen Granaldi, Christopher Hasson, and colleagues at Biocon BMS R&D Center for their technical assistance in participation of the in vivo studies and histological preparation of tissues. We thank Jia Zhu for his initial establishment of the rat valve surgical dissection method. All reported research was funded by Bristol-Myers Squibb Company.

AUTHOR CONTRIBUTIONS
F.W., C.Z., J.K., B.S., J.L., M.H., Y.S., and B.L. performed the experiments. F.W., J.K., C.Z., B.S., R.W., K.P., V.K.H., R.B., and K.A-R. contributed to experimental design and data analysis. K.A-R. supervised the study. F.W. and K.A-R. wrote the manuscript, which was edited by all authors.

DECLARATION OF INTERESTS
All authors are employees of BMS and may own shares of company stocks, but there are no conflicts of interest in regard to the disclosure of data associated with this study.

Received: March 3, 2020
Revised: November 21, 2020
Accepted: January 27, 2021
Published: March 19, 2021

REFERENCES
Anderton, M.J., Mellor, H.R., Bell, A., Sadler, C., Pass, M., Powell, S., Steele, S.J., Roberts, R.R., and Heier, A. (2011). Induction of heart valve lesions by small-molecule ALK5 inhibitors. Toxicol. Pathol. 39, 916–924.
Bartram, U., Molin, D.G., Wisse, L.J., Mohamad, A., Sanford, L.P., Doetschman, T., Speer, C.P., Poelmann, R.E., and Gittenberger-De Groot, A.C. (2001). Double-outlet right ventricle and overriding tricuspid valve reflect disturbances of looping, myocardialization, endocardial cushion differentiation, and apoptosis in TGF-beta(2)-knockout mice. Circulation 103, 2745–2752.
Chen, J.H., Yip, C.Y., Sone, E.D., and Simmons, C.A. (2009). Identification and characterization of aortic valve mesenchymal progenitor cells with robust osteogenic calcification potential. Am. J. Pathol. 174, 1109–1119.
Chen, X., Lu, H., Rateri, D.L., Cassis, L.A., and Daugherty, A. (2013). Conundrum of angiotensin II and TGF-beta interactions in aortic aneurysms. Curr. Opin. Pharmacol. 13, 180–185.
Cheng, S., and Lovett, D.H. (2003). Gelatinase A (MMP-2) is necessary and sufficient for renal tubular cell epithelial-mesenchymal transformation. Am. J. Pathol. 162, 1937–1949.
David, C.J., and Massague, J. (2018). Contextual determinants of TGFbeta action in development, immunity and cancer. Nat. Rev. Mol. Cell Biol. 19, 419–435.
Davidson, J.M. (2002). Smad about elastin regulation. Am. J. Respir. Cell Mol. Biol. 26, 164–166.
Dietz, H.C., Cutting, G.R., Pyeritz, R.E., Maslen, C.L., Sakai, L.Y., Corson, G.M., Puffenberger, E.G., Hamosh, A., Nanthakumar, E.J., Curristin, S.M., et al. (1991). Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 352, 337–339.
Elangbam, C.S. (2010). Drug-induced valvulopathy: an update. Toxicol. Pathol. 38, 837–848.
Fink B.E., Zhao Y., Borzilleri R.M., Zhang L., Kim K.S., Kamau M.G., Tebben A.J., Zhang Y., Donnell A.F. (2017) Bristol-Myers Squibb Company. TGFβR antagonists. US Patent 09708316.
Frazier, K., Thomas, R., Scicchitano, M., Mirabile, R., Boyce, R., Zimmerman, D., Grygielko, E., Nold, J., Degouville, A.C., Huet, S., et al. (2007). Inhibition of ALKS signaling induces physical dysplasia in rats. Toxicol. Pathol. 35, 284–295.
Frixen, U.H., Behrens, J., Sachs, M., Eberle, G., Voss, B., Warda, A., Lochner, D., and Birchmeier, W. (1991). E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J. Cell Biol. 113, 173–185.
Gellibert, F., De Gouville, A.C., Woolven, J., Mathews, N., Nguyen, V.L., Bertho-Ruault, C.,
Patikis, A., Grygielko, E.T., Lapin, N.J., and Huet, S. (2006). Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl]-N-(tetrahydro-2H-pyran-4-yl)benzamide (GW88388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor. J. Med. Chem. 49, 2210–2221.

Gordon, K.J., and Blobe, G.C. (2008). Role of transforming growth factor-beta superfamily signaling pathways in human disease. Biochim. Biophys. Acta 1782, 197–228.

Gotlib, A.I., Rosenthal, A., and Kazemian, P. (2002). Fibroblast growth factor 2 regulation of mitral valve interstitial cell repair in vitro. J. Thorac. Cardiovasc. Surg. 124, 591–597.

Gu, X., and Masters, K.S. (2010). Regulation of valvular interstitial cell calcification by adhesion peptide sequences. J. Biomed. Mater. Res. A 93, 1620–1630.

Han, R.I., Clark, C.H., Black, A., French, A., Culshaw, G.J., Kempson, S.A., and Corcoran, B.R. (2013). Morphological changes to endothelial and interstitial cells and to the extra-cellular matrix in canine myxomatous mitral valve disease (endocardiosis). Vet. J. 197, 388–394.

Herbertz, S., Sawyer, J.S., Stauber, A.J., Gueorguieva, I., Driscoll, K.E., Estrem, S.T., Cleverley, A.L., Desaih, D., Guba, S.C., Benhady, K.A., et al. (2015). Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des. Devel. Ther. 9, 4479–4499.

Hinck, A.P. (2012). Structural studies of the TGF-beta1 and their receptors - insights into evolution of the TGF-beta superfamily. FEBS Lett. 586, 1860–1870.

Hosper, N.A., Van Den Berg, P.P., De Rond, S., Popa, E.R., Wijmer, M.J., Masereeuw, R., and Bank, R.A. (2013). Epithelial-to-mesenchymal transition in fibrosis: collagen type I expression is highly upregulated after EMT, but does not contribute to collagen deposition. Exp. Cell Res. 319, 3000–3009.

Hulin, A., Deronne, C.F., Lambert, C.A., Dumont, B., Castronovo, V., Defraigne, J.O., Nusgens, B.V., Radermecker, M.A., and Collge, A.C. (2012). Metallothionein-dependent up-regulation of TGF-beta2 participates in the remodelling of the myxomatous mitral valve. Cardiovasc. Res. 93, 480–489.

Hulin, A., Deronne, C., Lambert, C., Defraigne, J.O., Nusgens, B., Radermecker, M., and Collge, A. (2013). Emerging pathogenic mechanisms in human myxomatous mitral valve: lessons from past and novel data. Cardiovasc. Pathol. 22, 245–250.

Kahari, V.M., Olsen, D.R., Rhudy, R.W., Carrillo, P., Chen, Y.Q., and Uitto, J. (1992). Transforming growth factor-beta signaling: another round of controversy. J. Genet. Genomics 37, 583–591.

Liu, R.M., and Desai, L.P. (2015). Reciprocal regulation of TGF-beta and reactive oxygen species: a perverse cycle for fibrosis. Redox Biol. 5, 565–577.

Liu, A.C., Joag, V.R., and Gotlieb, A.I. (2011). Transforming growth factor-beta regulates the growth of valve interstitial cells in vitro. Am. J. Pathol. 179, 1746–1755.

Liang, C.C., Park, A.Y., and Guan, J.L. (2001). In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat. Protoc. 2, 329–333.

Lin, F., and Yang, X. (2010). TGF-beta signaling in aortic aneurysm: another round of controversy. J. Genet. Genomics 37, 583–591.

Liu, A.C., Joag, V.R., and Gotlieb, A.I. (2007). The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology. Am. J. Pathol. 171, 1407–1418.

Liu, M.M., Flanagan, T.C., Lu, C.C., French, A.T., Argyle, D.J., and Corcoran, B.M. (2015). Culture and characterisation of canine mitral valve interstitial and endothelial cells. Vet. J. 204, 32–39.

Lorey, B., Chen, J., Neptune, E.R., Judge, D.P., Podowski, M., Holm, T., Meyers, J., Leitch, C.C., Katsanis, N., Sharifi, N., et al. (2005). A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat. Genet. 37, 275–281.

Maratara, K. (2009). The Effect of Transforming Growth Factor Beta 1 Receptor Kinase Inhibition on the Heart Valves of Sprague-Dawley Rats, PhD Thesis (Perdue University Graduate School, 2009 UMI), p. 3403130.

Martin, P. (1997). Wound healing–aiming for specific skin regeneration. Science 276, 75–81.

Martin, C.J., Datta, A., Littlefield, C., Kaira, A., Chapron, C., Wawersik, S., Degbey, K.B., Brueckner, C.T., Nikiforov, A., Daneyh, F.T., et al. (2020). Selective inhibition of TGFbeta1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape. Sci. Transl Med. 12, eaay8456.

Massague, J. (2008). TGFbeta in cancer. Cell 134, 215–230.

Massague, J., and Chen, Y.G. (2000). Controlling TGF-beta signaling. Genes Dev. 14, 627–644.

Noda, K., Babovic, B., Takagi, K., Inoue, T., Horiguchi, M., Hira, M., Fujikawa, Y., Akama, T.O., Kusumoto, K., Zilberg-Ler, L., et al. (2013). Latent TGF-beta binding protein 4 promotes fibroblast assembly by inhibiting TGF-β1. Proc. Natl. Acad. Sci. U S A 110, 2852–2857.

Powell, D.W., Mifflin, R.C., Valentich, J.D., Crowe, S.E., Saadi, J.I., and West, A.B. (1999). Myofibroblasts: I. Paracrine cells important in health and disease. Am. J. Physiol. 277, C1–C9.

Rak, G.D., White, M.R., Augustin-Rauch, K., Newsome, C., Graziano, M.J., and Schulze, G.E. (2020). Intermittent dosing of the transforming growth factor beta receptor 1 inhibitor, BMS-986260, mitigates class-based cardiovascular toxicity in dogs but not rats. J. Appl. Toxicol. 40, 931–946.

Rojas, A., Padidam, M., Cress, D., and Grady, W.M. (2009). TGF-beta receptor levels regulate the specificity of signaling pathway activation and biological effects of TGF-beta. Biochim. Biophys. Acta 1793, 1165–1173.

Sappino, A.P., Schurch, W., and Gabbiani, G. (1990). Differentiation repertoire of fibroblastic cells: expression of cytoskeletal proteins as marker of phenotypic modulations. Lab. Invest. 63, 146–161.

Schoen, F.J. (1997). Aortic valve structure-function correlations: role of elastic fibers no longer a stretch of the imagination. J. Heart Valve Dis. 6, 1–6.

Shi, Y., and Massague, J. (2003). Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113, 685–700.

Stauber, A.J., Credille, K., Truex, L.L., Elhhardt, W.J., and Young, J.K. (2014). Non-clinical safety evaluation of a transforming growth factor β receptor I kinase inhibitor in Fischer 344 rats and beagle dogs. J. Clin. Pract. 4, 1000196, https://doi.org/10.4172/2161-0495.196.

Stover, D.G., Bierie, B., and Moses, H.L. (2007). A delicate balance: TGF-beta and the tumor microenvironment. J. Cell. Biochem. 101, 851–861.

Tan, A.R., Alexe, G., and Reiss, M. (2009). Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer? Breast Cancer Res. Treat. 115, 453–495.

Taylor, P.M., Batten, P., Brand, N.J., Thomas, P.S., and Yacoub, M.H. (2003). The cardiac valve interstitial cell. Int. J. Biochem. Cell Biol. 35, 113–118.
Thiery, J.P., Acloque, H., Huang, R.Y., and Nieto, M.A. (2009). Epithelial-mesenchymal transitions in development and disease. Cell 139, 871–890.

Trefely, S., and Wellen, K.E. (2018). Metabolite regulates differentiation. Science 360, 603–604.

Turini, S., Bergandi, L., Gazzano, E., Prato, M., and Aldieri, E. (2019). Epithelial to mesenchymal transition in human mesothelial cells exposed to asbestos fibers: role of TGF-beta as mediator of malignant mesothelioma development or metastasis via EMT event. Int. J. Mol. Sci. 20, 150.

Vazquez-Villa, F., Garcia-Ocana, M., Galvan, J.A., Garcia-Martinez, J., Garcia-Pravia, C., Menendez-Rodriguez, P., Gonzalez-Del Rey, C., Barneo-Serra, L., and De Los Toys, J.R. (2015). COL11A1/(pro)collagen 11A1 expression is a remarkable biomarker of human invasive carcinoma-associated stromal cells and carcinoma progression. Tumour Biol. 36, 2213–2222.

Vesely, I. (1998). The role of elastin in aortic valve mechanics. J. Biomech. 31, 115–123.

Walker, G.A., Masters, K.S., Shah, D.N., Anseth, K.S., and Leinwand, L.A. (2004). Valvular myofibroblast activation by transforming growth factor-beta: implications for pathological extracellular matrix remodeling in heart valve disease. Circ. Res. 95, 253–260.

Weidinger, A., and Kozlov, A.V. (2015). Biological activities of reactive oxygen and nitrogen species: oxidative stress versus signal transduction. Biomolecules 5, 472–484.

Willis, B.C., and Borok, Z. (2007). TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease. Am. J. Physiol. Lung Cell. Mol. Physiol. 293, LS25–LS34.

Wiltz, D., Alexander Arevalos, C., Balaoing, L.R., Blanca, A.A., Sapp, M.C., Zhang, X., and Jane Grande-Allen, K. (2013). Extracellular Matrix Organization, Structure, and Function. In Calcific Aortic Valve Disease, E. Aikawa, ed.

Witt, W., Jannasch, A., Burkhard, D., Christ, T., Ravens, U., Brunnsen, C., Leuner, A., Morawietz, H., Matschke, K., and Waldow, T. (2012). Sphingosine-1-phosphate induces contraction of valvular interstitial cells from porcine aortic valves. Cardiovasc. Res. 93, 490–497.

Xie, F., Jin, K., Shao, L., Fan, Y., Tu, Y., Li, Y., Yang, B., Van Dham, H., Ten Dijke, P., Weng, H., et al. (2017). FAK1 phosphorylation by AKT accumulates TGF-beta type II receptor and drives breast cancer metastasis. Nat. Commun. 8, 15021.

Yingling, J.M., Blanchard, K.L., and Sawyer, J.S. (2004). Development of TGF-βi signalling inhibitors for cancer therapy. Nat. Rev. Drug Discov. 3, 1011.

Yoshioka, N., Kimura-Kuroda, J., Saito, T., Kawamura, K., Hisanaga, S., and Kawano, H. (2011). Small molecule inhibitor of type I transforming growth factor-beta receptor kinase ameliorates the inhibitory milieu in injured brain and promotes regeneration of nigrostriatal dopaminergic axons. J. Neurosci. Res. 89, 381–393.

Zhang, Y.E. (2009). Non-Smad pathways in TGF-beta signaling. Cell Res. 19, 128–139.

Zhang, Y., Zhao, Y., Tebben, A.J., Sheriff, S., Ruzanov, M., Feresteh, M.P., Fan, Y., Lippy, J., Swanson, J., Ho, C.P., et al. (2018). Discovery of 4-azaindole inhibitors of TGFbetaRI as immuno-oncology agents. ACS Med. Chem. Lett. 9, 1117–1122.
Supplemental Information

TGFβ2 and TGFβ3 mediate appropriate context-dependent phenotype of rat valvular interstitial cells

Faye Wang, Cindy Zhang, Jae Kwagh, Brian Strassle, Jinqing Li, Minxue Huang, Yunling Song, Brenda Lehman, Richard Westhouse, Kamalavenkatesh Palanisamy, Vinay K. Holenarsipur, Robert Borzilleri, and Karen Augustine-Rauch
Figure S1. Rat Valvular Interstitial Cells (VICs): characterization of cultured cells and morphologies, Related to Results Section “Rat Valvular Interstitial Cells: Characterization of Cultured Cells and Morphologies.”

(A) VICs exhibit multiple morphologies and grow by clonal expansion, where the respective morphology of the original cells is retained.
(B) Representative image of VIC cultured in a quiescent state induced by serum starvation (0.5% FBS) for 48 hours. In the quiescent state, primary rat VIC cultures present three morphologies:

(C) Condensed spindle-shaped (inset 2x original magnification).

(D) Flattened (inset 2x original magnification).

(E) Elongated, rounded morphology (inset 2x original magnification).

(F), (G) and (H) Immunofluorescent labeling for activated-VIC marker, α-SMA<sub>green</sub> and a mesenchymal marker, vimentin<sub>red</sub>. Nuclei labeled with DAPI<sub>blue</sub>. Cells were positive for vimentin with activated VICs positive for vimentin and strongly positive for α-SMA.

(I) and (J) Flow cytometric evaluation of rat spleen cells (I) and VICs (J) labeled with isotype or with anti-CD-31 antibody. Lack of staining in VICs indicated no endothelial cell contamination.

Scale bar= 200µm
Following 48 hour treatment, TGFβRi’s caused decreased transcription of myofibroblast targets (ACTA2 and Tagln) but increased expression of EMT targets (MMP2 and vimentin) and epithelial marker, E-cadherin. There was also decreased transcription of ECM targets (COL 1A1, COL 11A1 and Eln).

For each target, at least 3 TGFβRi-treated VIC samples were analyzed with 2 technical replicates (>6 PCR tests) in calculating ±SEM.

Figure S2. Early transcriptional alterations following TGFβRi treatment of VICS, Related to Table 4 and Figure 4.
**Figure S3.** Evaluation of VIC expression of phenotypic markers following 48 hours TGFβRi treatment, Related to Figure 5.

VICs were stained with antibodies against α-SMA, vimentin, CD-31 and EpCAM to determine status of phenotype. α-SMA and vimentin are expressed in all VICs but vimentin expression is increased in VICs treated with TGFβRi's. VICs remained negative for staining with the endothelial marker, CD-31, or epithelial marker, EpCAM, following TGFβRi treatment (data not shown).

Error bars represent ± SEM.

Statistical comparisons employed one-way or two-way ANOVA followed by Dunnett's Test.
Figure S4. Small interfering RNA knock down of respective TGFβs cause differential alterations of myofibroblast and collagen target expression, Related to Figure 6.

(A) Small interfering RNA (siRNA) constructs from multiple sources were evaluated for potency and selectivity of TGFβ ligand mRNA reduction at 16 hours post transfection. A total of 3-4 siRNA constructs for each ligand were evaluated with representative data for 1 or 2 constructs designed against each ligand are presented. All siRNA constructs designed for TGFβ2 or TGFβ3 decreased both TGFβ2 and TGFβ3 mRNA levels. Underlined bars represent the TGFβ ligand targeted by the respective siRNA construct.

(B) Silent RNA (10nM) knockdown of TGFβ ligands and effect on myofibroblast and collagen target transcription at 16 hours post siRNA transfection in rat VICs.

Represented data are the average of 3 experiments, ± SEM.
Statistical comparisons employed one-way or two-way ANOVA followed by Dunnett's Test. The p values are expressed as * $p \leq 0.05$; ** $p \leq 0.01$; ***$p \leq 0.005$; ****$p \leq 0.0001$
Table S1. TaqMan assays used in study, Related to Transparent Methods: RT-PCR.

| Gene symbol | Gene name                                      | Thermofisher Scientific Gene ID |
|-------------|------------------------------------------------|---------------------------------|
| Acta2       | Alpha smooth muscle actin                      | Rn01759928_g1                   |
| Cdh1        | E-cadherin                                     | Rn00580109_m1                   |
| Col1a1      | Collagen type I, alpha 1                       | Rn01463848_m1                   |
| Col11a1     | Collagen, type XI, alpha 1                     | Rn01523309_m1                   |
| ELN         | Elastin                                        | Rn01499782_m1                   |
| MMP2        | Matrix metallopeptidase 2                      | Rn01538170_m1                   |
| Tagln       | Transgelin                                     | Rn01642285_g1                   |
| TGFβRI      | Transforming growth factor, beta receptor I    | Rn00562811_m1                   |
| TGFβRII     | Transforming growth factor, beta receptor II   | Rn00579682_m1                   |
| TGFβRIII    | Transforming growth factor, beta receptor III  | Rn00568482_m1                   |
| TGFβ1       | Transforming growth factor, beta 1             | Rn00572010_m1                   |
| TGFβ2       | Transforming growth factor, beta 2             | Rn00676060_m1                   |
| TGFβ3       | Transforming growth factor, beta 3             | Rn00565937_m1                   |
| VIM         | Vimentin                                       | Rn00667825_m1                   |
| Hprt1       | Hypoxanthine phosphoribosyl transferase 1      | Rn01527840_m1                   |
Table S2. Antibodies used in immunohistochemical characterization (IHC), flow cytometry (Flow Cyt) and TGFβ neutralizing antibody studies (N), Related to associated sections in the Transparent Methods.

| Antibody                          | Assay     | Host species | Species reactivity          | Catalogue number and supplier | Dilution |
|-----------------------------------|-----------|--------------|-----------------------------|------------------------------|----------|
| Anti-α-SMA                        | IHC       | mouse        | mouse, human, cat. etc.     | ab184675, Abcam              | 1:100    |
| Anti Vimentin                     | IHC       | rabbit       | mouse, rat, human           | ab154207, Abcam              | 1:500    |
| IgG2a                             | IHC       | mouse        | mouse, rat, human           | ma5-18169, Invitrogen        | 1:200    |
| IgG                               | IHC       | rabbit       |                             | ab208568, Abcam              | 1:500    |
| E-cadherin Antibody (DECMA-1)     | IHC       | mouse        | rat, human, dog             | sc-59778, Santa Cruz         | 1:50     |
| Anti-mouse IgG (H+L), Alexa Fluor 488 | IHC     | donkey       | highly cross-absorbed       | A32766, Invitrogen           | 1:666    |
| Anti-Rabbit IgG (H+L), Alexa Fluor 594 | IHC   | donkey       | highly cross-absorbed       | A32754, Invitrogen           | 1:666    |
| Anti-SMA                          | Flow Cyt  | rabbit       | rat                         | ab223921, Abcam              | 1:200    |
| Anti-Vimentin                     | Flow Cyt  | mouse        | rat, horse, chicken, cow, cat, dog, human, pig | ab195877, Abcam | 1:500    |
| Anti-CD31                         | Flow Cyt/IHC | mouse   | mouse, rat, horse, chicken, cow, cat, dog, human, pig | 50-0310-82, Invitrogen | 0.25µg/test |
| IgG                               | Flow Cyt/IHC | rabbit    |                             | ab232814                     | 1:200    |
| IgG1                              | Flow Cyt/IHC | mouse     |                             | ab170190                     | 1:500    |
| IgG1                              | Flow Cyt/IHC | mouse     |                             | 50-4714-82, Invitrogen       | 0.25µg   |
| Anti-EpCAM                        | Flow Cyt/IHC | mouse     |                             | ab187276, abcam              | 1:50     |
| Goat Anti-Mouse IgG H&L Alexa Fluor® 488 | Flow Cyt/IHC | goat | mouse                        | ab150117, abcam              | 2 µg/ml |
| TGF beta-1,2,3 Monoclonal Antibody (1D11) | N           | mouse        | bovine, chicken, human, mouse | MA5-23795, ThermoFisher     | 1-10ug/ml |
| TGF-beta 1 Antibody (141322)      | N          | mouse        | human, rat, mouse           | MAB2401, Novus Biologicals  | 1-10ug/ml |
| TGF-beta 2 Antibody (771213)      | N          | rat          | mouse                       | MAB7346, Novus Biologicals  | 1-10ug/ml |
| TGF beta3 Antibody               | N          | goat         | mouse, human                | AF-243, Novus Biologicals   | 1-10ug/ml |
Table S3. IC₅₀ (µM) of Akt/mTOR phosphoprotein after 48 hours treatment with TGFβRi, Related to Table 2.

| TGFβRi   | AKT    | GSK3B  | IRSI    | p70S6K  |
|----------|--------|--------|---------|---------|
| LY2107961| 0.48±0.13 | 0.58±0.31 | 0.92±0.01 | 0.41±0.1 |
| BMT- A   | 0.19±0.07 | 0.24±0.12 | 0.34±0.33 | 0.18±0.07 |
| BMT- B   | 0.97±0.41 | 0.61±0.39 | 1.68±0.61 | 2.2±2.01 |

Average of 2 experiments; ±SEM.
Table S4. Flow cytometry analysis of apoptosis and necrosis of VICs at 48 hours following BMT-B treatment, Related to Table 3 and Figure 3.

| µM  | % of Dead cells | % of Apoptosis |
|-----|----------------|----------------|
| 0   | 4.4            | 1.4            |
| 0.01| 3.0            | 0.6            |
| 0.1 | 3.9            | 1.1            |
| 1   | 3.7            | 1.3            |
| 10  | 2.6            | 0.7            |
Table S5. Average of IC$_{50}$/EC$_{50}$ (µM) of target transcriptional expression at 48 hours treatment with TGFβR inhibitors, Related to Table 4 and Figure S2.

| Gene          | Category                  | Ly2109761 | BMT- A | BMT- B |
|---------------|---------------------------|-----------|--------|--------|
| TGFβ1 (IC$_{50}$) | TGFβ ligands              | 0.1613    | 0.12   | 0.43   |
| TGFβ2 (IC$_{50}$) | TGFβ ligands              | 0.1314    | 0.13   | 0.24   |
| TGFβ3 (IC$_{50}$) | TGFβ ligands              | 1.041     | 0.79   | ≥10    |
| TGFβRI (IC$_{50}$) | TGFβ receptors            | 0.1723    | 0.09   | 0.47   |
| TGFβRII (EC$_{50}$) | TGFβ receptors           | 0.42 ± 0.02 | 0.94 ± 0.53 | 0.56± 0.18 |
| TGFβRIII (EC$_{50}$) | TGFβ receptors           | 0.49 ± 0.045 | 0.58 ± 0.24 | 0.61± 0.22 |
| ACTA2 (IC$_{50}$) | Myofibroblast Marker  | 0.15 ± 0.06 | 0.14 ± 0.02 | 0.87 ± 0.67 |
| Tagln (IC$_{50}$) | Myofibroblast Marker     | 0.12 ± 0.04 | 0.40 ± 0.33 | 0.17 ± 0.11 |
| Cdh1 (EC$_{50}$) | Epithelial Marker        | 0.41      | 0.14   | 1.18   |
| VIM (EC$_{50}$)  | Mesenchymal Marker       | 0.017     | 0.33   | 0.4    |
| MMP2 (EC$_{50}$) | MMP2 EMT Marker          | 0.48 ± 0.36 | 0.07 ± 0.05 | 0.05   |
| COL1A1 (IC$_{50}$) | ECM                      | 0.27 ± 0.14 | 0.09 ± 0.03 | 0.31 ± 0.15 |
| COL11A1 (IC$_{50}$) | ECM                      | 0.25 ± 0.12 | 0.40 ± 0.22 | 0.53 ± 0.11 |
| ELN (IC$_{50}$) | ECM                      | 0.15 ± 0.06 | 0.07 ± 0.02 | 0.71 ± 0.52 |

For each target, at least 3 TGFβRi- treated VIC samples were analyzed with 2 technical replicates (≥6 PCR tests) in calculating EC$_{50}$/IC$_{50}$, respectively. In cases that included multiple experiments, the EC$_{50}$/IC$_{50}$ values are presented with ±SEM.
**Transparent Methods**

*Rat VIC isolation.* All animal procedures were approved by the Institutional Animal Care and Use Committee of Bristol-Myers Squibb Company and were conducted in accordance with the Guide for the Care and Use of Laboratory Animals. Male or female Crl:CD® (Sprague-Dawley) rats (Charles River Laboratories, Kingston, NY) between 8-13 weeks were used in the surgical harvest of heart valves to provide VICs for culture. Approximately 1-2 rats were used to support sufficient VICs for culture, where passages 3-8 were used to support in vitro experiments. Tissue harvest and VIC cultures were re-established after passage 8 to support additional in vitro experiments. Rat valves (mitral, tricuspid, pulmonary and aortic) were isolated according to previous methods (Liu et al., 2015, Walker et al., 2004) with some modification. Briefly, heart valves were isolated under sterile conditions, rinsed in cold phosphate buffered saline (PBS) and placed on ice, then centrifuged followed by two digestions. The initial digestion was to remove endothelial cells with 1 ml of digested collagenase solution (MillporeSigma, C5894) at 600 units/ml in 1X Trypsin inhibitor, 0.1% BSA, 100 units/ml penicillin/ 100 µg/ml streptomycin (P/S, ThermoFisher Scientific, 15140122) and media 199 (ThermoFisher Scientific, 11150-067). Samples were incubated 37°C for 5 minutes, followed by pipetting 5 times, then the media without valves was removed as much as possible. The second digestion was performed to disassociate the VICs from the collagen network using 10ml of media containing collagenase at 42.5 units/ml at 37°C for 60 minutes with shaking at 50 times/minute. After washing with PBS twice with centrifugation, cells were placed in four wells of a 24 well plate in 10% (V:V) fetal bovine serum (FBS, ThermoFisher Scientific, 10082147), P/S with media 199 (complete medium). After 7-10 days, when cells reached confluence, cells were transferred to a 6-well plate. All additional cell passages came from the original 24 and 6-well plates and were harvested by cell scraping. VICs were maintained in complete media that contained one third of previous passage media as conditioned media. For cell passages used for experiments, detached cells were cultured in a collagen I (MillporeSigma,125-50) coated T-75 flask for 5-7 days with media change every 2-3 days and cells were removed by incubation for 3 minutes at 37°C with Trypsin-EDTA (0.05%) (ThermoFisher Scientific, 25300054), and plated in 24, or 96 well plates.

**TGFβR Inhibitors.** Three TGFβRi’s with potent TGFβRI or -R1/-R2 selectivity were evaluated in this study to assess target/class mediated alterations of VIC biology: LY2109761, BMT-A and BMT-B. LY2109761 is an orally active TGFβRI/II dual kinase inhibitor (I, $K_i = 38$ nmol/L; II, $K_i = 300$ nmol/L in vitro kinase assay) (Melisi et al., 2008), purchased from Selleckchem, cat. # S2704. BMT-A and BMT-B, are TGFβRI inhibitors of the azaindole series, with BMT-A also having inhibitory activity on TGFβRII, were synthesized by Bristol-Myers Squibb (Table 1) (Zhang et al., 2018). The structure of BMT-A and BMT-B can be found as Example 14B and 47, respectively (Fink et al 2017, US Patent 09708316). All compounds were formulated in dimethyl sulfoxide (DMSO, MillporeSigma, D2438) as 20mM stock solutions.

*Rat In Vivo Toxicology Studies:* All animal experiments were approved by the Institutional Animal Care and Use Committee of Bristol-Myers Squibb Company and were conducted in accordance with the Guide for
the Care and Use of Laboratory Animals. Male or female Sprague-Dawley rats (Newsted et al., 2019) of approximately 8-10 weeks age were treated daily by oral gavage with the respective TGFβRi for 4 days, with necropsy on Day 14 or 15. In the case of LY2109761, rats were dosed for 4 days or 14 days with necropsy on day 4 or day 15, and confirmed previous reports that doses that caused valvulopathy were not histologically apparent by Day 4 but was obvious by 2 weeks with either 4 days or 14 days of dosing (Herbertz et al., 2015, Maratera, 2009). Based upon finding that 4 days of dosing with LY2109761 was sufficient to induce valvulopathy that was histologically apparent by 2 weeks post initial dose, BMT-A and BMT-B were subsequently evaluated following a dose schedule of 4 consecutive days followed by a 10 day dose holiday prior to necropsy and tissue collection. On day 1-2 plasma was collected along a time course for toxicokinetic evaluation. Hearts were collected and fixed in 10% neutral buffered formalin, paraffin embedded and step-sectioning was performed to thoroughly evaluate integrity all heart valves. Valves were stained with hematoxylin and eosin or trichrome for histopathological assessment. At least 5 rats were included in each treatment group.

**VIC Experimental Designs.** Rat VICs were plated and cultured with complete media (without conditioned media) for 2-3 days to achieve ≤90% of coverage in either 96 or 24 well plates. The VICs were then serum starved at least 24 hours in M199 with 0.5% of FBS prior to treatments with the TGFβRi's (Gu and Masters, 2010). With exception of the SMAD3 phosphorylation studies, all experiments were undertaken as follows: after treatment with a concentration range (0.01, 0.1, 1, 3, 10 µM) of TGFβRi’s or 0.05% DMSO in serum starved media, cells were evaluated for various biological endpoints at 48 hours post treatment. For the p-SMAD3 phosphorylation studies, cells were lysed and processed for p-SMAD3 AlphaLISA measurements at 1 hour or 48 hours post TGFβRi treatment. When stimulating with human TGFβ (hTGFβ, VWR, 47743-604), 0.1ng/ml of hTGFβ in 0.1% BSA/PBS was added 30 minutes prior cell collection for p-SMAD3 measurement, with exception of the time course study of hTGFβ induced p-SMAD3 assay. To evaluate p-SMAD3 induction following hTGFβ stimulation, hTGFβ concentrations were tested in a concentration range of 0.001 -10 ng/ml.

**Flow cytometry assessment:** Approximately 1 × 10⁶ cells in 1 mL PBS were labeled with 1 µl of the reconstituted fluorescent reactive dye to 1 mL of the cell suspension for 30 minutes with protection from light. Live and dead cells were distinguished by using a viability dye, LIVE/DEAD™ Fixable Near-IR dye (ThermoFisher Scientific, L34976). The fluorescence of Near-IR dye with 633 nm excitation and 780 nm emission was detected through APC-Cy7 channel.

Cell apoptosis was evaluated by using CellEvent™ Caspase-3/7 Green Detection Reagent (Invitrogen, C10423). Cells were incubated with 100 µl of 5 µM CellEvent™ Caspase-3/7 Green Detection Reagent in PBS with 5% fetal bovine serum for 30 minutes at 37°C. Apoptotic cells with activated caspase-3/7 show bright green nuclei was detected through FITC channel.
Cultured VIC cells treated with BMS-A, BMS-B, or LY2109761 for 48h were collected for flow cytometric phenotyping. The cells were stained with Anti-rat CD31-eFluor660 (Invitrogen, cat. 50-0310-82), alpha smooth muscle actin-Allophycocyanin (abcam, ab223921), vimentin-Alexa Fluor® 488 (abcam, ab195877) and Anti-CD31 antibodies. (Table S2).

All flow cytometry experiments were run by using BD FACSCanto II flow cytometer with Diva software.

**VIC proliferation, ATP and oxidative stress assessment.** At 48 hours following treatment, VICs were evaluated for proliferation by CyQUANT® Direct Cell Proliferation Assay (ThermoFisher Scientific, C35011). VICs were cultured for 60 minutes with 2X CyQUANT test reagent, and fluorescence was read at wavelengths of 480/535 nm using an EnVision plate reader (Perkin-Elmer, Waltham, MA). ATP measurement was undertaken using CytoTox™ Homogeneous Membrane Integrity Assay (Promega, G7890) and chemoluminescent signal was read by the EnVision plate reader after a 15 minute incubation with CellTiter-Glo® reagent. Oxidative Stress was evaluated using the ROS-Glow™ H₂O₂ Assay (Promega, G8821). To this end, VICs were cultured with H₂O₂ at the last 6 hours of the experiment, following 48 hours of compound treatment. Following the 6 hour H₂O₂ treatment, the VICs were then incubated for 20 minutes with ROS-Glo™ Detection Solution. Chemiluminescence was measured using an EnVision plate reader.

**Mitochondria function measurement.** An extracellular flux assay was used to assess mitochondrial toxicity in VICs by determining the oxygen consumption rate (OCR) utilizing the XF®96 flux analyzer (Agilent), as described by (Brand and Nicholls, 2011). Briefly, rat VICs were plated onto XF®96 plates (Agilent), cultured, and test compounds were applied as described in VIC Experimental Designs. The cells were washed twice in un-buffered DMEM assay medium: XF Base Medium Minimal DMEM (Agilent Technologies, 103680), supplemented with 10mM glucose, 1mM pyruvate, 2mM L-glutamine (medium pH7.4, 37°C). Cells were then incubated in 180µl assay media in a CO₂ free incubator at 37°C for 60min. The XF® 96 microplate cartridges were loaded with 20 µl of dosing solution. Three measurements of OCR were taken and a mitochondrial stress test was performed by consecutive addition of the ATP synthase inhibitor, oligomycin (1 µM), the uncoupler, carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP, 0.5 µM) and finally the ETC inhibitors rotenone (1µM) plus antimycin A (1µM) (Rot/AA). Five functional parameters including ATP production, maximal respiration, spare capacity, proton leak, and non-mitochondrial respiration, were calculated to determine potential mitochondrial toxicity caused by tested compounds.

**RT-PCR.** VICs were treated with TGFβRi’s for 48 hours in triplicate in a 96-well plate then lysed according to TaqMan® Gene Expression Cells-to-CT™ Kit (ThermoFisher Scientific, AM1728); 10µl of lysis was used for reverse transcription at 37°C for 1 hour, then 2µl of RT product was used in the real time PCR reaction. TaqMan primer assay (ThermoFisher Scientific, 4426961) sets (Table S1) were used to
characterize the VIC’s response to TGFβRi’s. PCR amplification was conducted using a ViiA7 system from ThermoFisher Scientific.

Phospho-protein measurement. VICs were cultured in 96 or 24 well plates and treated with TGFβRi’s at a concentration range of 0.01, 0.1, 1, 3, 10 µM or 0.05% DMSO at 37°C for 60 minutes or 48 hours, according to the experimental design. Plates were washed with ice-cold PBS, then 1X MILLIPEX®MAP lysis buffer (Millipore, 43-040) with complete proteinase inhibitor (Roche, 11 836 153 001), phosphate cocktail II (Sigma, P5726) and phosphate cocktail III (Sigma P0044) were added. The lysate was gently rocked for 10 minutes at 4°C, then filtered with a filter plate (EMD, MAHVH 4510) and centrifuged at 2000g, 4°C for 5 minutes. p-SMAD3 was detected using an AlphaLISA® SureFire Ultra HV p-SMAD3 (Ser423/425) test kit (PerkinElmer, ALSU-PSM3-A-HV). p-SMAD signal was measured using an EnVision plate reader, PerkinElmer, 2105. p-SMAD2, p-AKT and p-ERK were measured with Luminex technology - MILLIPEX MAP TGFβ Signaling Pathway, Magnetic Bead 6-Plex-Cell Signaling Multiplex Assay (Millipore, 48-614MAG) and Akt/mTOR phosphoprotein were tested with the same method (Millipore, 48-611MAG).

TGFβ ligand Measurement: TGFβ ligand Measurement: TGF-β1, 2, and 3 levels in rat serum and cell culture media were detected by using Bio-Rad Luminex kit (Bio-Plex Pro TGF-β 3-plex Panel, 171W4001M). The detailed experimental protocol is described in Bio-Rad’s Bio-Plex Pro™ TGF-β Assays Instruction Manual, https://www.bio-rad.com/en-us/sku/171w4001m-bio-plex-pro-tgf-beta-3-plex-assay?ID=171w4001m. Briefly, animal serum samples or filtered cell culture media were diluted either 16X or 4X with sample diluent or cell culture media and acidified with 1N HCl and neutralized with 1N NaOH/0.5 M HEPES to release TGF-β from latent complex. The samples were then incubated with magnetic beads with internal color-code multiple fluorescent dyes, detection antibody, and streptavidin-PE. A Bio-Plex® 200 Systems and Bio-Plex Manager™ software were used for sample acquisition and data analysis. The concentration of analyte bund to each bead is proportional to the MFI of reporter signal, and the result was presented as median fluorescence intensity (MFI) as well as concentration (pg/ml). A standard curve of TGF-β1, 2 and 3 were run with the samples in each assay.

VIC Cell Migration: VICs were seeded at 2.5X10⁵/well in 6-well plates. At confluence, media was switched to 0.5%FBS/M199 media for 24 hours. At Scratch Test was performed where a scratch was made in the middle of the well with a 200µl pipette tip (Liang et al., 2007), then respective TGFβRi’s (10µM) in 0.5%FBS/M199 media was added to the wells. Three independent wells were photographed at 0, 6, 24 and 48 hours post-scratch using a Zeiss phase contrast microscope, where photographs were taken at the same marked location each time. The TIF files were analyzed using HALO image analysis software (INDICA LABS, NM, USA). The annotation of the scratched open area was performed for 0 hour image, and then the annotation was copied and pasted for its sequential 6, 24, and 48 hour. The measurement of
the cell density was performed by using the Area Quantification v1.0 algorithm. Thus, the area of the cells was measured and the percentage of cell density were calculated and compared to the Time 0 (T0) density.

**ELISA Measurement of Collagen and Elastin in VIC lysates:** VICs were cultured in 24 well plates. Following 48 hours of treatment with TGFβRi's, cells were lysed with 1X MILLIPLEX®MAP lysis buffer with complete proteinase inhibitor, phosphate cocktail II and phosphate cocktail III and 50ul of lysate was tested by ELISA with rat Col type1 (MyBioSource.com, MBS262647), rat Col type III (cat No., MyBioSource.com, MBS260802), rat Col typeV (MyBioSource.com, MBS2603034), rat Elastin (MyBioSource.com, MBS2503127). Manufacture procedures were followed for each respective ELISA measurement.

**Cellular Impedance measurement:** After background readings of Agilent E-Plate (Aligent, 300601110) were taken with 50ul of complete media, 15,000 cells/100 µL were seeded into the E-Plate. The plate was then transferred to the Agilent real time cell analyzer (RTCA) station, which was located in a cell culture incubator, and cells were cultured for 24 hours at 37°C, followed by another 24 hours with 0.5%FBS/Media199, continued by treatment with TGFβRi's in a 0.01 to 10µM concentration range, in 0.5%FBS/Media199. Cell attachment, spreading, and proliferation were assessed as impedance recordings, which were monitored every 2 hrs starting after cell seeding through 5 days. Measured cellular impedance (CI) from cells in each individual well on the E-Plate were automatically converted to CI values by the RTCA software. CI value from TGFβRi's added at 72 hrs and continued to be monitored for an additional 48 hours were exported to Excel for further analysis.

**Immunocytochemistry and Imaging.** VIC morphology was observed by light microscopy during the culture period and assessed for cell morphology and confluence. For immunocytochemistry, 0.5 X 10⁴/well cell suspension was added on BioCoat™ Collagen I 4 wells chamber slides, (VWR, 734-0206) and incubated in 5% CO₂ at 37°C for 24-48 hours. After serum starving and treatment with TGFβRi's for 48 hours, slides were directly fixed with ice cold 100% methanol for 5 minutes, permeabilized with 0.1% Triton X-100 in 1 X PBS for 5 minutes and then blocked for 1 hour with 3% CD1 mouse plasma in PBST (PBS + 0.1% Tween 20) at room temperature. Primary antibodies against vimentin, α-SMA, α-CD31, α- E cadherin and α-Epcam in PBST with 1% of BSA were applied for one hour at room temperature in the dark. Following a wash sequence, secondary antibodies were applied for 1 hour at room temperature in the dark. After another wash sequence, slides were mounted using ProLong® Gold Antifade Mountant with DAPI (ThermoFisher Scientific, USA). Images were collected using a 20x objective on an LSM710 confocal microscope (Carl Zeiss, Thornwood, NY). Using the tiling/stitching software feature and an automated stage, a high-resolution image that covered the majority of the well was created. Details of the antibodies used for immunohistochemistry are summarized in (Table S2).

**Silent RNA knockdown of TGFβ ligands.** Three constructs were evaluated for transfection efficiency, target knockdown efficiency and selectivity, and cytotoxicity. The original set of evaluated constructs were from Integrated DNA Technologies: rn.Ri.TGFβ1.13, rn.Ri. TGFβ2.13, and rn.Ri.TGFβ3.13, three
constructs of each, named 13.1; 13.2 and 13.3. Due to the finding that all siRNAs for TGFβ2 and TGFβ3 caused knockdown of both TGFβ2 and TGFβ3 gene expression, Ambion® Silencer® Select Pre-designed siRNA (select TGFβ2 and select TGFβ3) were evaluated (Figure S4A). Based on acceptable transfection efficiency, selectivity in target knockdown and lack of cytotoxicity, siRNA TGFβ2 (ID s135786) and siRNA TGFβ3 (ID s130564) from ThermoScientifics and rn.Ri.TGFβ1.13.2 of Integrated DNA technologies were selected for this study and used with the X-tremeGENE™ siRNA (Sigma Aldrich, cat# 4476093001). 0.5%FBS in M199 media as the dilution solution.

**TGFβ ligand neutralization studies:** After VICs were starved for 24 hour, pan TGF beta Monoclonal Antibody (1D11) (ThermoFisher Scientific, MA5-23795), TGF-beta 1 Antibody (141322) (NOVUS biologicals, MAB2401), TGF-beta 2 Antibody (771213) (NOVUS biologicals, MAB7346) and/or TGF beta3 (NOVUS biologicals, AF-243) (Table S2) were added at 1,3,10 µg/ml with 1XPBS as control in 0.5%FBS/M199 media for 48 hours. Cells were measured for p-SMAD3 inhibition by alphalisa and gene expression by real time PCR by a set of TaqMan primers (Table S1). Cell media was collected and measured for TGFβ ligand levels using Luminex.

Statistical analysis and EC_{50}/IC_{50} calculations. Data are presented in all tables and figures as mean ± standard deviation or standard error of the mean. The data were analyzed for significant changes with respect to the vehicle or DMSO vs. treatment using GraphPad Prism 8.0.2 (La Jolla, CA) with statistical significance defined at least \( p \leq 0.05 \). Statistical comparisons employed one-way or two-way ANOVA followed by Dunnett’s Test. The data calculated for EC_{50} and IC_{50} was transformed and nonlinear regression fit using same program. Unless otherwise noted, the p values are expressed as * \( p \leq 0.05 \); ** \( p \leq 0.01 \); *** \( p \leq 0.005 \); **** \( p \leq 0.0001 \)
Supplemental References

BRAND, M. D. & NICHOLLS, D. G. 2011. Assessing mitochondrial dysfunction in cells. Biochem J, 435, 297-312.

FINK B.E., ZHAO Y., BORZILLERI R.M., ZHANG L., KIM K.S., KAMAU M.G., TEBBEN A.J., ZHANG Y., DONNELL A.F.
Bristol-Myers Squibb Company. TGFβR antagonists. US Patent 09708316. July 18, 2017

GU, X. & MASTERS, K. S. 2010. Regulation of valvular interstitial cell calcification by adhesive peptide sequences. J Biomed Mater Res A, 93, 1620-30.

HERBERTZ, S., SAWYER, J. S., STAUBER, A. J., GUEORGUIEVA, I., DRISCOLL, K. E., ESTREM, S. T., CLEVERLY, A. L., DESAIAH, D., GUBA, S. C., BENHADJI, K. A., SLAPAK, C. A. & LAHN, M. M. 2015. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des Devel Ther, 9, 4479-99.

LIANG, C. C., PARK, A. Y. & GUAN, J. L. 2007. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc, 2, 329-33.

LIU, M. M., FLANAGAN, T. C., LU, C. C., FRENCH, A. T., ARGYLE, D. J. & CORCORAN, B. M. 2015. Culture and characterisation of canine mitral valve interstitial and endothelial cells. Vet J, 204, 32-9.

MARATERA, K. 2009. The effect of transforming growth factor beta type 1 receptor kinase inhibition on the heart valves of Sprague-Dawley rats. . PhD Thesis Perdue University Graduate School, 2009 UMI:3403130.

MELISI, D., ISHIYAMA, S., SCLABAS, G. M., FLEMING, J. B., XIA, Q., TORTORA, G., ABBRUZZESE, J. L. & CHIAO, P. J. 2008. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther, 7, 829-40.

NEWSTED, D., BANERJEE, S., WATT, K., NERSESIAN, S., TRUESDELL, P., BLAZER, L. L., CARDARELLI, L., ADAMS, J. J., SIDHU, S. S. & CRAIG, A. W. 2019. Blockade of TGF-beta signaling with novel synthetic antibodies limits immune exclusion and improves chemotherapy response in metastatic ovarian cancer models. Oncoimmunology, 8, e1539613

WALKER, G. A., MASTERS, K. S., SHAH, D. N., ANSETH, K. S. & LEINWAND, L. A. 2004. Valvular myofibroblast activation by transforming growth factor-beta: implications for pathological extracellular matrix remodeling in heart valve disease. Circ Res, 95, 253-60.

ZHANG, Y., ZHAO, Y., TEBBEN, A. J., SHERIFF, S., RUZANOV, M., FERESHTEH, M. P., FAN, Y., LIPPY, J., SWANSON, J., HO, C. P., WAUTLET, B. S., ROSE, A., PARRISH, K., YANG, Z., DONNELL, A. F., ZHANG, L., FINK, B. E., VITE, G.
D., AUGUSTINE-RAUCH, K., FARGNOLI, J. & BORZILLERI, R. M. 2018. Discovery of 4-Azaindole Inhibitors of TGFbetaRI as Immuno-oncology Agents. ACS Med Chem Lett, 9, 1117-1122.